Page 11234..1020..»

Archive for the ‘Skin Stem Cells’ Category

After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness – Here And Now

Every year, about 10,000 people in the U.S. need a stem cell transplant but cant find a donor.

The intense medical procedure, which can help those with leukemia, lymphoma, sickle cell anemia and other blood diseases, can save lives but securing a donor can be like finding a needle in a haystack.

Be The Match is a nonprofit, national registry where people can sign up to donate their stem cells. More than 35 million people around the world have volunteered yet only a small percentage of those donors are Americans, and even the registry admits most Americans dont know it exists.

The mother of a 12-year-old boy with leukemia has set out to change that.

Mandy Goldman is a hairdresser who lives with her husband and four children outside Boston. She remembers the devastating day five years ago when doctors told her the chemotherapy they gave her son Mateo Goldman, 9 years old at the time, didnt work.

They told us that our only option of curing Mateo was a bone marrow transplant, she says, a risky procedure that often involves a host of complications. But they had no other choice, she says.

The family got to work on the monumental task finding Mateo Goldman a close enough match.

Linda Matchan first reported the Goldman familys experience for The Boston Globe. In her research, she found very, very few people had any awareness of the need for bone marrow and stem cells donors. The awareness campaign around the subject is severely lacking compared to other campaigns like the importance of donating blood, she says.

For example, there's a little boy right now in North Carolina named Thor Forte, who's 10 and has sickle cell disease. And he has been waiting for literally half his life, five years, for a donor to be available, Matchan says. He's a tough match, but they finally did find somebody. And then when the time came for the procedure, the person backed out. So two years later, the boy is still waiting.

Fortunately, quickly after finding out Mateo Goldman didnt match with anyone in his family, he was paired with a donor on the registry from Germany. Mandy Goldman says Laura Stterlin of Frankfurt was ready to go and donate, ultimately saving her son.

Mateo Goldman wrote Stterlin, whose name he did not know at the time, a thank you note reading: Dear Donor, thank you for giving me the bone marrow. You feel like youre already part of my family, he says.

And unlike usual Make-A-Wish requests, Mateo Goldman asked to meet Stterlin in person halfway across the world. The trip to Germany was planned for summer of 2020 but has since been canceled due to the pandemic.

In 2019 when she was reporting this story, Matchan had a trip planned to Germany. She ended up meeting Stterlin and hearing the story of how she became a donor. Stterlin said she was at a sporting event with her husband when she got hungry and went on the hunt for some grub.

Dear Donor, thank you for giving me the bone marrow. You feel like youre already part of my family.

Germany has a robust public service campaign to get citizens to donate bone marrow, Matchan says. So it came to no surprise to Stterlin when she came across a kiosk to sign up.

Just three months later, she got a call and an email from the registry saying that there is somebody in the United States for whom she could be a match and was asked if she would donate, Matchan says. A couple of days later, she went into the hospital and did the donation.

Stterlins stem cells then crossed the Atlantic Ocean, making their way to America during a snowstorm.

The cells started working in Mateo Goldman right away but not without some difficulties, Mandy Goldman says. He battled total body stiffness from graft-versus-host disease, a complication of the transplant.

But, you know, Matteo's an amazing kid, she says, so through it all, he was smiling and making the best of it, even though he was suffering for a lot of the time.

Two years later, in July of 2020, the cancer came back. But since Mateo Goldmans first transplant, the science had evolved greatly.

So much so that his older brother, Leo Goldman, became a candidate to donate his cells for the second stem cell transplant.

I didn't realize how I could get my brother's cells, Mateo Goldman, now 12 years old, says. Once that sank in, I felt that it would connect me and my brother more.

Right before Christmas last year, the family got extraordinary news: Mateo Goldman had zero cancer in his bone marrow, Mandy Goldman says.

Now the mom of four is on a mission to raise awareness on stem cell donations and share the story of how it saved her sons life.

The amazing feeling Leo got from being able to be the person who saved his brother's life is something he's going to carry with him forever, she says. And even Laura [Stterlin], she gave him three and a half years of his life that we get to spend with him. I just really want to educate people about how empowering it is to do something so incredible for somebody else.

When she started talking to others to raise awareness, she was shocked to discover how fearful people were in committing to be a donor.

If people could see the trauma these patients go through her son had a drain placed in his stomach, total body radiation, chemotherapy that left him head-to-toe in a skin-burning rash she says then maybe they wouldnt be scared to dedicate a small action for someone whose only cure is through a stem cell transplant.

Once people are educated about how much of a difference it makes, she says, then I feel like they would do it.

Click here to learn more about the Be The Match Registry.

Tinku Rayproduced and edited this interview for broadcast.Serena McMahonadapted it for the web.

More:
After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now

Leukemia in children: Symptoms, causes, treatment, outlook, and more – Medical News Today

Leukemia is a type of cancer that affects the blood. The two most common types in children are acute lymphoblastic leukemia and acute myelogenous leukemia.

In a person with leukemia, blood cells are released into the bloodstream before they are fully formed, so there are fewer healthy blood cells in the body.

Below, we describe the types of childhood leukemia, the symptoms, and the treatments. We then look at when to contact a doctor, what questions to ask, and where to find support.

Childhood leukemia is the most common form of cancer in children. It affects up to 3,800 children under the age of 15 in the United States each year.

Leukemia occurs when bone marrow releases new blood cells into the bloodstream before they are fully mature.

These immature blood cells do not function as they should, and eventually, the number of immature cells overtakes the number of healthy ones.

Leukemia can affect red and white blood cells and platelets.

The bone marrow produces stem cells. A blood stem cell can become a myeloid stem cell or a lymphoid stem cell.

Lymphoid stem cells become white blood cells. Myeloid stem cells can become:

Leukemia is typically acute or chronic, and chronic types are rare in children. They can include chronic myeloid leukemia or chronic lymphocytic leukemia.

Most childhood leukemias are acute, meaning that they progress quickly and need treatment as soon as possible.

Acute lymphoblastic leukemia (ALL) is the most common type in children, accounting for 75% of childhood leukemia cases.

It affects cells called lymphocytes, a type of white blood cell.

In a person with ALL, the bone marrow releases a large number of underdeveloped white blood cells called blast cells. As the number of these increases, the number of red blood cells and platelets decreases.

There are two subtypes of ALL: B-cell and T-cell.

In most childhood cases of ALL, the cancer develops in the early forms of B-cells. The other type, T-cell ALL, typically affects older children.

Research from 2020 reports that the majority of people diagnosed with ALL are under 18 and typically between 2 and 10 years old.

The American Cancer Society report that children under 5 years old have the highest risk of developing ALL and that this risk slowly declines until a person reaches their mid-20s.

The outlook for ALL depends on the subtype, the persons age, and factors specific to each person.

Myeloid leukemias account for approximately 20% of childhood leukemia cases, and most myeloid leukemias are acute.

Acute myelogenous leukemia (AML) affects white blood cells other than the lymphocytes. It may also affect red blood cells and platelets.

AML can begin in:

Juvenile myelomonocytic leukemia (JMML) accounts for approximately 12% of leukemia cases in children.

This rare type is neither acute nor chronic. JMML begins in the myeloid cells, and it typically affects children younger than 2 years.

Symptoms can include:

The symptoms of leukemia may be nonspecific similar to those of other common childhood illnesses.

A doctor will ask how long the child has been experiencing the symptoms, which can include:

Children may experience specific symptoms depending on the type of blood cell that the leukemia is affecting.

A low number of red blood cells can cause:

A low number of healthy white blood cells can cause infections or a fever with no other sign of an infection.

A low platelet count can cause:

Various factors can increase a childs risk of leukemia, and most are not preventable.

The following genetic conditions can increase the risk of leukemia:

Also, having a sibling with leukemia may increase the risk of developing it.

These can include exposure to:

If a child has symptoms that might indicate leukemia, a doctor may perform or request:

A bone marrow aspiration involves using a syringe to take a liquid sample of bone marrow cells. The doctor may give the child a drug that allows them to sleep through this test.

During the diagnostic process, a person might ask:

The doctor may recommend a variety of treatments for childhood leukemia, and the best option depends on a range of factors specific to each person.

The treatment usually consists of two phases. The first aims to kill the leukemia cells in the childs bone marrow, and the second aims to prevent the cancer from coming back.

The child may need:

Before or during treatment, a person might ask the doctor:

Questions to ask after the treatment might include:

Children who have undergone leukemia treatments require follow-up care, as the treatments often cause late effects.

These can develop in anyone who has received treatment for cancer, and they may not arise for months or years after the treatment has ended.

Treatments that can cause late effects include:

These complications may affect:

The late effects that may come can also depend on the type of treatment and the form of leukemia.

Because many leukemia symptoms can also indicate other issues, it can be hard to know when to contact a doctor.

Overall, it is best to seek medical advice if a child shows symptoms or behaviors that are not normal for them.

If a child has received a leukemia diagnosis, the effects can extend to parents, other family members, caregivers, and friends.

A person can find support and additional resources from:

The following organizations based in the United Kingdom also provide support and guidance:

Childhood leukemia can affect mental health, as well as physical health.

Learn more about mental health resources here.

According to the American Cancer Society, most children with leukemia have no known risk factors. There is no way to prevent leukemia from developing.

Because there are very few lifestyle-related or environmental causes of childhood leukemia, it is very unlikely that a caregiver can do anything to help prevent the disease.

A childs outlook depends on the type of leukemia. It is important to keep in mind that current estimates do not take into account recent advances in technology and medicine.

For example, the most recent 5-year survival rate estimates reflect the experiences of children who received their diagnoses and treatments more than 5 years ago.

The American Cancer Society report that the 5-year survival rate for children with ALL is 90%. The same rate for children with AML is 6570%.

Childhood leukemia is typically acute, which means that it develops quickly. As a result, a person should contact a doctor if they notice any of the symptoms.

The most common type of childhood leukemia is ALL, representing 3 out of 4 leukemia cases in children.

Treatment may include a combination of chemotherapy, targeted drugs, immunotherapy, stem cell transplants, surgery, and radiation.

The prognosis depends on the type of leukemia and the childs age.

This diagnosis can affect mental as well as physical health, and the effects can extend to caregivers, family members, and friends. Many different resources are available for support.

The rest is here:
Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today

Paragon Biosciences Expands Cell And Gene Therapy Platform – Contract Pharma

Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence, has launched CiRC Biosciences, a cell therapy company developing treatments for serious diseases with high, unmet needs with an initial focus on the eye."The addition of CiRC Biosciences to our portfolio builds upon our cell and gene therapy platform, an area that has tremendous potential to address serious genetic diseases," said Jeff Aronin, founder, chairman and chief executive officer, Paragon Biosciences. "CiRC Biosciences gives us the science to target retinal diseases that could lead to vision restoration with numerous other applications in the years ahead."CiRC Biosciences is currently advancing pre-clinical development of chemically induced retinal cells for vision restoration in Geographic Atrophy Age-Related Macular Degeneration (Dry AMD), which is the most common cause of irreversible vision loss over the age of 65, and advanced Retinitis Pigmentosa (RP), a genetic disorder that causes tunnel vision and eventual blindness. There are no U.S. Food & Drug Administration (FDA) approved treatments to restore vision loss in Dry AMD or RP.The company's novel mechanism of action is designed for direct chemical conversion of fibroblasts into other cell types using a cocktail of small molecules in an 11-day chemical conversion process. Pre-clinical studies have shown efficacy in blind mice that demonstrated vision restoration. CiRC Biosciences has provisional patent applications to protect its platform."Our technology transforms ordinary skin cells into specialized retinal cells using a cocktail of small molecules," said Sai Chavala, M.D., co-founder and chief scientific officer, CiRC Biosciences. "This process is potentially safer, quicker, more cost effective and easier to manufacturer than using traditional stem cells. Working with Paragon Biosciences to build and advance CiRC Biosciences provides us the opportunity to efficiently progress this technology through research and development stages.CiRC Biosciences first reported its discovery in the highly respected scientific journal Nature (April 15, 2020). A recently published New England Journal of Medicine article (Nov. 5, 2020) discussed CiRC's technology of using chemically induced cells to restore retinal function. The article concluded, "The new and emerging strategies for the rescue, regeneration, and replacement of photoreceptors suggest a bright future in the fight to preserve and restore vision in blinding eye diseases."The abstract in Nature is available here.Access to the NEJM article is available here.

Excerpt from:
Paragon Biosciences Expands Cell And Gene Therapy Platform - Contract Pharma

[Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT – Dove Medical Press

Introduction

Head and neck squamous cell carcinoma (HNSCC) is one of the major causes of cancer-associated illness and death, with more than 600,000 newly diagnosed cases worldwide each year1 and a continuously increasing incidence rate.2 HNSCC includes cancers of the oral cavity, pharynx, and larynx. The anatomical structures of the head and neck can be damaged by the tumor itself or treatments such as surgical resection and chemoradiotherapy, which sometimes cause speech, swallowing, and breathing impairments.3,4 Patients with HNSCC have been shown to bear greater psychological distress than those with other types of cancer.5

Despite the currently available therapies, patients with advanced HNSCC still experience poor outcomes.68 For example >50% of patients with locoregionally advanced HNSCC experience recurrence or metastases development within 3 years of treatment.911 Treatment options for patients with the recurrent and metastatic disease following progression after a platinum-based regimen are limited, and the median overall survival of such patients is less than 7 months.1215

The recurrence and metastasis of HNSCC are facilitated by immune evasion;16 therefore, as one of the methods to inhibit immune evasion, the use of programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway inhibitors is considered effective in the treatment of recurrent HNSCC.1719 Nivolumab, a fully human IgG4 antiPD-1 monoclonal antibody, has shown remarkable antitumor efficacy and safety when administered to patients with recurrent HNSCC whose disease had progressed within 6 months of platinum-based chemotherapy;19 Furthermore, nivolumab treatment has been shown to improve the quality of life of these patients.20 However, PD-1 inhibitors can upregulate T cells in vivo, which may lead to the development of graft-versus-host disease (GVHD) in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT).2123 To the best of the authors knowledge, no studies have investigated the safety and efficacy of nivolumab in patients with HNSCC after allo-HSCT. Here, we report the case of a patient who experienced excellent control of left buccal squamous cell carcinoma with nivolumab after the failure of platinum-based chemotherapy despite receiving allogeneic bone marrow transplantation.

Without any family history of tumor, a 33-year-old man was diagnosed with Philadelphia chromosome-positive T cell acute lymphoblastic leukemia on March 19, 2014. He received one course of vincristine and prednisone therapy and four courses of vincristine, daunorubicin, cyclophosphamide, and prednisone therapy. He was in complete remission at the end of therapy. Subsequently, allogeneic bone marrow transplantation was performed; the donor was his human leukocyte antigen (HLA)-haploidentical sibling (sister). He experienced chronic GVHD (c GVHD) of the oral cavity and skin 3 months after transplantation, for which he was treated with steroid hormone- and cyclosporine-based therapies. Skin rejection lasted for more than 3 years. Imatinib mesylate was administered for 2 years after transplantation, and his leukemia was well controlled.

In August 2018, the patient developed an ulcer of approximately 0.5 0.5 cm size in the left buccal mucosa; the ulcer was slightly painful and covered with white moss. In September 2018, the patient was admitted to Peking University Stomatological Hospital, where a biopsy of the buccal mucosa was performed. The pathology results showed the presence of squamous cell carcinoma in the left cheek. Unfortunately, this patient was not a right candidate for HNSCC in terms of exposure to risk factors, such as long terms of smoking and drinking. On October 10, 2018, 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (CT) showed that the mass in the left cheek was metabolically active, which is consistent with the activity of a malignant tumor. One course of an adjuvant therapy regimen (nimotuzumab [200 mg d0] + docetaxel [60 mg d1, 8]+ nedaplatin [60 mg d2, 3]) was administered on October 26, 2018. Following this, the patient developed degree II thrombocytopenia and redness, swelling, and ulceration of the cheek, which had discharge with a peculiar smell. On November 29, 2018, a head and neck CT scan showed a left buccal malignant tumor with the destruction of the neighboring mandibular bone and lymph node enlargement in the left submaxillary region and right carotid sheath. The CT examination revealed disease progression. Following a multidisciplinary consultation in our hospital, surgery was not recommended; instead, a chemotherapy-based comprehensive treatment was recommended as a better option for the patient. The patient received chemotherapy with albumin paclitaxel (200 mg d1, 8)+ bleomycin (15,000 units d2, 9) from November 30, 2018 to January 9, 2019. On another CT scan, the curative effect was evaluated as partial remission (showed in Video 1, Figure 1A); subsequently, two courses of a chemotherapy regimen comprising nivolumab (140 mg d1) + albumin paclitaxel (200 mg d1, d8) were administered. A CT examination showed stable disease (SD) on March 12, 2019, following which the patient was administered 120 mg of nivolumab once every 2 weeks from March 15 to May 23, 2019. Another CT examination was performed on May 28, 2019 (showed in Video 2, Figure 1B). During the therapy course, the related tumor markers showed an overall downward trend, the new metastases did not appear, the patients status became better than before. Subsequently, another CT examination performed in August 02, 2019 showed the extent of the tumor was obvious reduction than before (showed in video 3, Figure 1C). And the corresponding CT report in August 02, 2019 was described as follows Compared with the CT on 28 May, 2019, the extent of the tumor in the left cheek became obviously smaller, the tubercle in the left submandibular and the lymph nodes in the left neck also became smaller. There were no other significant changes in this image. Most importantly, the patient did not develop any form of GVHD following nivolumab administration.

Figure 1 Head and neck CT images showing tumor before (A) and after treatment with nivolumab (B, C, respectively).

Abbreviation: CT, computed tomography.

Note: The arrows indicate the maximum length diameter of tumor or tumor site.

Reliable data on the clinical safety and efficacy of nivolumab in the treatment of recurrent or metastatic HNSCC have been obtained in a Phase III randomized clinical trial (CheckMate 141).19 In this trial, 361 patients with recurrent HNSCC for whom disease had progressed within 6 months after platinum-based chemotherapy were enrolled between May 29, 2014, and July 31, 2015. The median follow-up duration for overall survival (OS) was 5.1 months (range, 016.8 months). OS was significantly greater in patients randomized to receive nivolumab than in those who received standard second-line, single-agent systemic therapy with either methotrexate, docetaxel, or cetuximab (hazard ratio, 0.70; 97.73% confidence interval (CI), 0.510.96; P = 0.01). The median OS was 7.5 months (95% CI, 5.59.1) in the nivolumab group versus 5.1 months (95% CI, 4.06.0) in the standard therapy group. The one-year survival was also greater in patients who received nivolumab than in those who received standard therapy (36.0%vs. 16.6%). Furthermore, the response rate was higher in those who received nivolumab than in those who received standard therapy (13.3% vs 5.8%); however, the median progression-free survival was not significantly different between the groups (2.0 vs 2.3 months; P=0.32). In this study, patients who were treated with nivolumab had a longer OS than those treated with standard therapy, regardless of tumor PD-L1 expression or p16 status. Grade 3 or 4 treatment-related adverse events occurred in 13.1% of patients who received nivolumab and 35.1% of those who received standard therapy. Physical function, role functioning, and social functioning were stable in the nivolumab group, whereas they were substantially worse in the standard therapy group.20 Moreover, among Asian patients, the survival benefits were consistent with the global group.24

It was unclear whether nivolumab could be used in patients with recurrent HNSCC after allo-HSCT, though Khaddour et al proved the efficacy and safety of Pembrolizumab in patients who underwent allo-HSCT after relapsed and refractory Szary Syndrome and cutaneous squamous cell carcinoma.25 However, some case reports (Table 1) and clinical trials (Table 2) have reported the efficacy and safety of nivolumab when administrated to patients with recurrent hematological malignancies (mostly Hodgkins lymphoma) after allo-HSCT.

Table 1 Case Reports of Nivolumab Use After Allo-HSCT

Table 2 Studies on Nivolumab Use After Allo-HSCT

In Herbaux et al, nivolumab (3 mg/kg, once every 2 weeks) was administered to 20 patients with Hodgkins lymphoma who experienced relapse after allo-HSCT. The overall response rate was 95%, the 1-year progression-free survival rate was 58.2%, and the 1-year OS rate was 78.8%.26 Compared with other treatment options, nivolumab was more effective in these patients.2730 Haverkos et al reported results after a median follow-up duration was 428 days (range, 133833 days). After treatment with PD-1 inhibitors [nivolumab 3 mg/kg, once every 2 weeks (n = 28) and pembrolizumab (n =3)], the overall response rate of 31 patients with relapsed lymphoma after allo-HSCT was 77%, the median progression-free survival was 591 days (range,400644 days), and 68% of the patients survived to the end of the study.23 These two studies showed that nivolumab is effective when administered to patients with recurrent blood cancers after allo-HSCT, which is consistent with the results of several other case reports3134 and case series.35,36 The PD-1/PD-L1 pathway plays a key role in the regulation of the balance among T cell activation, T-cell tolerance, and immune-mediated tissue damage. This pathway protects healthy cells from excessive inflammatory or autoimmune responses.37,38 Some studies have shown that the activation of the PD-1/PD-L1 pathway can reduce acute and chronic GVHD, whereas its blockade can accelerate the graft-versus-host response and increase the associated mortality.21,22,39 It is unclear whether the PD-1 inhibitor nivolumab increases the risk of GVHD and the associated mortality in patients after allo-HSCT.23,26 Some clinical studies and case reports have shown that nivolumab treatment-related GVHD and consequent death in patients after allo-HSCT might be affected by the following factors. First, GVHD after antiPD-1 treatment has been observed most frequently in matched sibling donor transplants; for which Haverkos et al reported an incidence of 75%.23 In a Phase I pilot study, without GVHD or G3/G4 immune toxicity after receiving multiple doses of nivolumab was only among one patient whose donor source was Haploidentical+cord blood Fludarabine.40 Second, a history of GVHD, especially for the acute GVHD, may lead to an increased risk of nivolumab treatment-related GVHD after allo-HSCT. In a French cohort, all patients who presented with acute GVHD after nivolumab treatment had a prior history of acute GVHD, among which three patients presented with steroid-refractory nivolumab-induced GVHD, and GVHD was not observed among patients without a history of GVHD.26 This phenomenon was also observed in Steinerovs medical report.41 In the study by Haverkos et al, 63% of patients with a history of GVHD prior to antiPD-1 treatment developed treatment-emergent GVHD after receiving antiPD-1.23 Third, the shorter the interval between transplantation and nivolumab use, the greater the risk of GVHD. In the study by Herbaux et al, the median intervals between transplantation and nivolumab use in cases with the presence and absence of GVHD were 8.5 months and 28.5 months, respectively.26 In another study by Wang et al, the reported four patients all experienced immune-related adverse events following nivolumab treatment and the median time from transplantation to nivolumab use was 7.8 months.40 Fourth, dose is a risk factor for nivolumab treatment-related GVHD. In a case report, chronic skin GVHD was observed when the dose of nivolumab was adjusted from 0.5 mg/kg to 2 mg/kg.33 Other factors, such as immunosuppressive therapy at the time of nivolumab administration, may also influence nivolumab treatment-related GVHD. Recently, a comprehensive literature review was launched by Awais et al to assess the safety and efficacy of the use of checkpoint inhibitors (ipilimumab, nivolumab and pembrolizumab) in blood cancers before and after allo-HSCT. Collective data showed that checkpoint inhibitors use after allo-HSCT for post-transplant relapse had higher efficacy but the risk of GVHD was significant. Moreover, the investigation indicated that higher drug doses, shorter intervals between checkpoint inhibitors exposure and allo-HSCT and prior history of GVHD had a positive correlation with the risk of GVHD.42

In the present case, HNSCC was effectively controlled without any nivolumab treatment-related acute or chronic GVHD after nivolumab administration, while the weight loss being the only adverse event. After comprehensive analysis, we found that many factors may impede the development of nivolumab treatment-related GVHD in our patient. On one hand, the appropriate donor, no use of checkpoint inhibitors prior to allo-HSCT, the long interval between nivolumab administration and allo-HSCT (36 months) and the standard dose use of nivolumab were the negative factors for GVHD development. On the other hand, the chronic GVHD of the oral cavity and skin before nivolumab use might lead to the development of GVHD. However, it remained unknown what role the immunosuppressant therapy played in the occurrence of GVHD, though we definitely known that immunosuppressant was administered more than 2 years after allo-HSCT and discontinued for 2 years before treatment with nivolumab in our patient. Finally, whether the two primary cancers in our case affected the efficacy and safety of nivolumab by some unknown pathways were unclear, which needed further exploration.

Nivolumab has been shown to be effective in patients with HNSCC for whom platinum-based therapy has failed. However, little is known about the efficacy and safety of nivolumab in patients with HNSCC who have undergone allo-HSCT. Our case report shows that nivolumab could be used effectively and safely in such patients, however, more clinical trials are required to confirm these results.

This study was approved by the Medical Ethics Committee of Tianjin Medical University Cancer Institute and Hospital. The authors state that they have obtained verbal and written informed consent from the patient for the inclusion of their medical and treatment history within this case report.

This work was supported by the Tianjin Science and Technology Commission (18ZXXYSY00070), Key Task Project of Tianjin Health and Family Planning Commission (16KG128), Anticancer Key Technologies R&D Program of Tianjin (12ZCDZSY16200), and Natural Science Foundation of Tianjin (18JCYBJC91600).

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359E386. doi:10.1002/ijc.29210

2. Jakobsen KK, Gronhoj C, Jensen DH, et al. Increasing incidence and survival of head and neck cancers in Denmark: a nation-wide study from 1980 to 2014. Acta Oncol. 2018;57:11431151. doi:10.1080/0284186X.2018.1438657

3. Sobecki-Ryniak D, Krouse HJ. Head and neck cancer: historical evolution of treatment and patient self-care requirements. Clin J Oncol Nurs. 2013;17(6):659663. doi:10.1188/13.CJON.659-663

4. Licitra L, Mesia R, Keilholz U. Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck. Oral Oncol. 2016;52:1823. doi:10.1016/j.oraloncology.2015.10.020

5. Singer S, Krauss O, Keszte J, et al. Predictors of emotional distress in patients with head and neck cancer. Head Neck. 2012;34(2):180187. doi:10.1002/hed.21702

6. Licitra L, Felip E. Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):121122. doi:10.1093/annonc/mdp149

7. Adelstein D, Gillison ML, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 2.2017. J Natl Compr Canc Netw. 2017;15(6):761770. doi:10.6004/jnccn.2017.0101

8. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(45):309316. doi:10.1016/j.oraloncology.2008.06.002

9. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):19451952. doi:10.1056/NEJMoa032641

10. Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):3340. doi:10.1016/j.radonc.2011.05.036

11. Tanvetyanon T, Padhya T, McCaffrey J, et al. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2015;37(6):840845. doi:10.1002/hed.23684

12. Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised Phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004;40(14):20712076. doi:10.1016/j.ejca.2004.05.019

13. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer. 2008;112(12):27102719. doi:10.1002/cncr.23442

14. Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013;31(11):14051414. doi:10.1200/JCO.2012.45.4272

15. Saloura V, Cohen EEW, Licitra L, et al. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2014;73(6):12271239. doi:10.1007/s00280-014-2459-z

16. Ferris RL. Immunology and Immunotherapy of head and neck cancer. J Clin Oncol. 2015;33(29):32933304. doi:10.1200/JCO.2015.61.1509

17. Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):38383845. doi:10.1200/JCO.2016.68.1478

18. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956965. doi:10.1016/S1470-2045(16)30066-3

19. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):18561867. doi:10.1056/NEJMoa1602252

20. Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single-agent therapy of investigators choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, Phase 3 trial. Lancet Oncol. 2017;18:11041115. doi:10.1016/S1470-2045(17)30421-7

21. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171:12721277. doi:10.4049/jimmunol.171.3.1272

22. Saha A, Aoyama K, Taylor PA, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013;122:30623073. doi:10.1182/blood-2013-05-500801

23. Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221228. doi:10.1182/blood-2017-01-761346

24. Kiyota N, Hasegawa Y, Takahashi S, et al. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigators choice in recurrent squamous cell carcinoma of the head and neck: a subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol. 2017;73:138146. doi:10.1016/j.oraloncology.2017.07.023

25. Khaddour K, Musiek A, Cornelius LA, et al. Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for szary syndrome. J Immunol Cancer. 2019;7:338. doi:10.1186/s40425-019-0801-z

26. Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed hodgkin lymphoma. Blood. 2017;129:24712478. doi:10.1182/blood-2016-11-749556

27. Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for hodgkins lymphoma. J Clin Oncol. 2011;29:971978. doi:10.1200/JCO.2010.32.1711

28. Anastasia A, Carlo-Stella C, Corradini P, et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the fondazione Italiana linfomi. Br J Haematol. 2014;166:140142. doi:10.1111/bjh.12821

29. Carlo-Stella C, Ricci F, Dalto S, et al. Brentuximab vedotin in patients with hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers. Oncologist. 2015;20:323328. doi:10.1634/theoncologist.2014-0420

30. Tsirigotis P, Danylesko I, Gkirkas K, et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:13131317. doi:10.1038/bmt.2016.129

31. Angenendt L, Schliemann C, Lutz M, et al. Nivolumab in a patient with refractory Hodgkins lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:443445. doi:10.1038/bmt.2015.266

32. Yared JA, Hardy N, Singh Z, et al. Major clinical response to nivolumab in relapsed/refractory hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:850852. doi:10.1038/bmt.2015.346

33. Onizuka M, Kojima M, Matsui K, et al. Successful treatment with low-dose nivolumab in refractory hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol. 2017;106:141145. doi:10.1007/s12185-017-2181-9

34. Shad AT, Huo JS, Darcy C, et al. Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: a case report. Pediatr Blood Cancer. 2017;64. doi:10.1002/pbc.26257

35. Godfrey J, Bishop MR, Syed S, Hyjek E, Kline J. PD-1 blockade induces remissions in relapsed classical hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. J Immunol Cancer. 2017;5:11. doi:10.1186/s40425-017-0211-z

36. El Cheikh J, Massoud R, Abudalle I, et al. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in hodgkin lymphoma. Bone Marrow Transplant. 2017;52:10741077. doi:10.1038/bmt.2017.69

37. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677704. doi:10.1146/annurev.immunol.26.021607.090331

38. Francisco LM, Sage PT, Sharpe AH, The PD-1. pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219242.

39. Fujiwara H, Maeda Y, Kobayashi K, et al. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease. J Immunol. 2014;193:25652573. doi:10.4049/jimmunol.1400954

40. Wang AY, Kline J, Stock W, et al. Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26:10251027. doi:10.1016/j.bbmt.2020.01.021

41. Steinerov K, Jindra P, Lysk D, Karas M. Development of resistant GvHD in a patient treated with nivolumab for hodgkins lymphoma relapse after allogeneic unrelated transplantation. Klin Onkol. 2019;32:6669. doi:10.14735/amko201966

42. Ijaz A, Khan AY, Malik SU, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25:9499. doi:10.1016/j.bbmt.2018.08.028

43. Albring JC, Inselmann S, Sauer T, et al. PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation. Bone marrow transplantation. 2017. doi:10.1038/bmt.2016.274

44. Covut F, Pinto R, Cooper BW, et al. Nivolumab before and after allogeneic hematopoietic cell transplantation. Bone marrow transplantation. 2017. doi:10.1038/bmt.2017.44

45. Herbaux C, Gauthier J, Brice P, et al. Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC. Blood. 2015. doi:10.1182/blood.V126.23.3979.3979

46. Schoch LK, Borrello I, Fuchs EJ, et al. Checkpoint Inhibitor Therapy and Graft Versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with Post-Transplant Cyclophosphamide. Blood. 2016. doi:10.1182/blood.V128.22.4571.4571

47. Davids MS, Kim HT, Costello C, et al. Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. Blood. 2017. doi:10.1182/blood.V130.Suppl_1.275.275

Link:
[Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press

Two Studies Shed Light on How and Where the Body Can Add New Fat Cells – Technology Networks

Gaining more fat cells is probably not what most people want, although that might be exactly what they need to fight off diabetes and other diseases. How and where the body can add fat cells has remained a mystery - but two new studies from UT Southwestern provide answers on the way this process works.

The studies, both published online in Cell Stem Cell, describe two different processes that affect the generation of new fat cells. One reports how fat cell creation is impacted by the level of activity in tiny organelles inside cells called mitochondria. The other outlines a process that prevents new fat cells from developing in one fat storage area in mice - the area that correlates with the healthy subcutaneous fat just under the skin in humans. (Both studies were done in mice.)

In the second study, a commonly used cancer drug was able to jump-start healthy fat cell creation in mice, a finding that raises the possibility of future drug treatments for humans.

While fat isn't popular, as long as people overeat they will need a place to store the excess calories, explains Philipp Scherer, Ph.D., director of the Touchstone Center for Diabetes Research at UT Southwestern and senior author of the first study focusing on mitochondria. There are two options, he says: squeezing more lipids (fat) into existing fat cells and ballooning their size, leading to problems such as inflammation and, eventually, diabetes; or creating new fat cells to help spread the load. Fat stored properly - in fat cell layers under the skin (subcutaneous fat) that aren't overburdened instead of around organs (visceral fat) or even inside organs - is the healthy alternative, he says.

Problems follow if existing fat cells are left on their own to become engorged, adds Rana Gupta, Ph.D., associate professor of internal medicine and senior author of the second study. "When these cells are so overwhelmed that they can't take it anymore, they eventually die or become dysfunctional, spilling lipids into places not intended to store fat."

Those lipids may move into the liver, leading to fatty liver disease; to the pancreas, resulting in diabetes; or even to the heart, causing cardiovascular disease, Gupta says. Visceral, or belly fat, may surround the organs, creating inflammation.

The healthiest place to store fat is in subcutaneous fat, adds Gupta. Ironically, that is where mice in his study were least able to create new fat cells, despite the fact that stem-cell-like progenitor cells primed to become fat cells were present there as well, he says.

Gupta's study identified a process that prevents progenitor cells from developing into fat cells in mouse subcutaneous inguinal fat.

The protein HIF-1a (short for hypoxia-inducible factor-1 alpha) is central to the process. It kicks off a series of cellular actions that ultimately inactivate a second protein called PPARgamma, the key driver of fat cell formation.

These proteins are found in both humans and mice. In fact, in a culture of human subcutaneous fat cell progenitors, HIF-1a also inhibited new fat cells from being created, according to Gupta.

In Gupta's mouse study, researchers used a genetic approach to inhibit HIF-1a and found that the progenitor cells could then make subcutaneous inguinal fat cells and fewer were inflamed or fibrotic.

Next, they tested the cancer drug imatinib (brand name Gleevec) and found it had the same effect. The cancer drug was tried because it was known to have beneficial effects against diabetes in cancer patients with both diseases, Gupta says.

In Scherer's study, researchers manipulated a protein called MitoNEET in the outer membrane of the precursor cells' mitochondria, organelles known as the cells' power plants. The resulting mitochondrial dysfunction and drop in cell metabolism caused precursor cells to lose the ability to become new fat cells and increased inflammation.

"This study shows we can manipulate the precursor cells' willingness to become fat cells," Scherer says. "The ability to recruit new fat cells by tickling these pre-fat cells to become fat cells is very important and has profound beneficial effects on health, particularly in the obesity-prone environment that we all live in."

He says his goal is now to design a drug that could stimulate mitochondrial activity.

"Understanding the mechanism is an important first step," Scherer says, referring to the findings from the two studies. "We will have to learn in the future how to manipulate these processes pharmacologically."

Reference: Joffin N, Paschoal VA, Gliniak CM, et aI. Mitochondrial metabolism is a key regulator of the fibro-inflammatory and adipogenic stromal subpopulations in white adipose tissue. Cell Stem Cell. doi:doi.org/10.1016/j.stem.2021.01.002

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Two Studies Shed Light on How and Where the Body Can Add New Fat Cells - Technology Networks

Heidi Klum loves to pamper her skin with goodies from Drunk Elephant and Glossier – woman&home

With her sun-kissed hair and flawless golden skin, it's easy to forget that Heidi Klum is in her mid 40s. Genetics certainly help. But so do Heidi Klum's favourite skincare products by Glossier and Drunk Elephant, plus a reminder of home courtesy of German beauty brand The Cream by Augustinus Bader.

In a rare selfie, Klum showed off the Perfectil Hair Skin And Nails Vitamins she takes daily, alongside this smorgasbord of beauty products, which proves the supermodel takes her skincare seriously.

Here are some of her favourite products:

More from womanandhome:

Drunk Elephant T.L.C. Framboos Glycolic Resurfacing Night Serum

This night serum contains a hefty dose of glycol acid to exfoliate built-up dead skin cells and resurface dull, uneven skin. Expect brighter, smoother skin when you wake.

Drunk Elephant T.L.C. Sukari Babyfacial 25% AHA + 2% BHA Mask

If you like to feel a product working, you'll positive love this mask. Like an AHA/BHA facial in a bottle, it resurfaces skin to reveal greater clarity and improved skin tone.

Drunk Elephant C-Firma Day Serum

This vitamin C day serum is packed with antioxidants to protect skin from urban aggressors.

Glossier Solution

A liquid exfoliator that you apply a bit like toner, it buffs away dead dulling skin with a single swipe.

Mario Badescu Drying Lotion

We know, we know, even supermodels get spots. This cult zit lotion contains salicylic acid, sulfur, and zinc oxide to dry up blemishes - fast.

Augustinus Bader The Rich Cream

The brainchild of a stem cell scientist no less, this overnight treatment uses amino acids and vitamins to re-energise cells to repair damage more effectively.

Read more:
Heidi Klum loves to pamper her skin with goodies from Drunk Elephant and Glossier - woman&home

When to take fish oil: Timing, dosages and side effects – Medical News Today

There is no incorrect time of day to take fish oil supplements. However, some evidence suggests that people absorb omega-3 fatty acids more effectively when they take them with a meal that contains dietary fat.

This comes from a study in Current Opinion in Clinical Nutrition and Metabolic Care.

Fish oil is a major source of omega-3 fatty acids, which may have a number of health benefits.

In this article, we will discuss when people should take fish oil, how to take it, dosage, and any health benefits and side effects.

There is no significant benefit to taking fish oil at a specific time of day. However, people may wish to take fish oil with a meal that contains dietary fat.

A 2019 study on omega-3 found that taking an omega-3 concentrate with food that contains fat increased bioavailability, making it easier for the body to absorb.

Additionally, an older 2015 study found that taking omega-3 fatty acids with a low fat meal reduced absorption.

Both of these studies looked at omega-3 fatty acids specifically, so the results may not apply to people taking fish oil. Additionally, the amount of omega-3 in fish oil can vary, depending on factors such as the type of fish, and the brand.

People can take fish oil capsules with water during a meal. If a person typically does not eat much fat at breakfast, they may wish to wait until lunch or their evening meal before taking it.

Some people experience gastrointestinal side effects when taking fish oil. If a person experiences this side effect, they may find it helpful to split their fish oil into two doses and take them at different times of the day.

People who split their dose in half may need to take each one at different mealtimes.

Researchers have found it difficult to define an optimal amount of omega-3 fatty acids to get per day.

The American Heart Association (AHA) recommend adults take between 5001,000 milligrams of omega-3 per day. However, other countries and organizations recommend different doses.

The Office of Dietary Supplements (ODS) note that while some types of omega-3 have no official recommended dose, alpha-linolenic acid (ALA) is an exception. This table shows the recommended daily amounts by age and sex:

The amount of ALA in omega-3 supplements can depend on the type of supplement and the manufacturer. Read the product label to determine how much a supplement contains.

Omega-3 fatty acids may have a positive effect on human health in a number of ways. Research into its benefits is ongoing, but there is evidence that it may:

However, many studies on omega-3s health benefits focus on getting these fatty acids from fish and seafood, rather than from fish oil capsules. If a person is thinking of taking fish oil for a health condition, they should speak with a doctor first.

Some specific conditions that may benefit from a higher intake of omega-3 include:

According to a 2015 review, there is some evidence that consuming omega-3 fatty acids may help prevent or manage cardiovascular conditions. Omega-3 fatty acids may help reduce triglyceride levels in the blood and reduce the risk of cardiovascular death.

Omega-3 fatty acids may also have antiarrhythmic effects, which means they help a persons heart beat in a regular pattern. The effect that omega-3 fatty acids have on arrhythmia may significantly reduce the risk of fatal ventricular arrhythmias.

However, more recent studies show that there may not be a clear benefit to taking omega-3 to prevent adverse effects of cardiovascular conditions. There is also some evidence that taking statins at the same time as omega-3 fatty acid supplements may reduce their protective effect on cardiovascular conditions.

Scientists need to carry out more research on omega-3 and its relationship with preventing or managing cardiovascular diseases.

Some studies have shown that a high omega-3 intake can reduce the risk of inflammatory disease mortality.

Some have also found that omega-3 fatty acids are beneficial for people with Crohns disease and ulcerative colitis, two types of inflammatory bowel disease.

However, there is no clinically significant evidence on whether omega-3 fatty acids help prevent relapses for people with these conditions.

Several in vitro studies show that omega-3 fatty acids have an effect on colorectal cancer stem cells (CCSC). CCSC have a long lifespan and can self-renew, leading to colon tumors.

CCSC can lead to cancer relapse and chemotherapy resistance. Omega-3 fatty acids may stop CCSC from growing and may reduce chemotherapy resistance.

Omega-3 fatty acids may have several positive effects with regards to prostate cancer, although research on this is mixed.

Several studies have found that consuming fish or omega-3 fatty acids reduces the risk of developing prostate cancer, including aggressive forms.

However, other studies suggest that there is no clear benefit to consuming omega-3 fatty acids to prevent prostate cancer.

Side effects of fish oil supplements are usually mild. They include:

Additionally, omega-3 supplements can have an adverse interaction with drugs that affect blood clotting.

People should contact their healthcare provider to ensure it is safe for them to take a supplement before trying it.

Some evidence suggests that taking supplements that contain omega-3 with a meal that contains fat can increase absorption. As a result, people may wish to take fish oil at breakfast, lunch, or dinner. However, there is no correct or incorrect time to take it.

Always speak with a doctor before starting a new supplement. If a person experiences side effects, they may benefit from splitting their dose in two.

Read this article:
When to take fish oil: Timing, dosages and side effects - Medical News Today

Heidi Klum loves to pamper her skin with goodies from Drunk Elephant and Glossier – Woman & Home

With her sun-kissed hair and flawless golden skin, it's easy to forget that Heidi Klum is in her mid 40s. Genetics certainly help. But so do Heidi Klum's favourite skincare products by Glossier and Drunk Elephant, plus a reminder of home courtesy of German beauty brand The Cream by Augustinus Bader.

In a rare selfie, Klum showed off the Perfectil Hair Skin And Nails Vitamins she takes daily, alongside this smorgasbord of beauty products, which proves the supermodel takes her skincare seriously.

Here are some of her favourite products:

More from womanandhome:

Drunk Elephant T.L.C. Framboos Glycolic Resurfacing Night Serum

This night serum contains a hefty dose of glycol acid to exfoliate built-up dead skin cells and resurface dull, uneven skin. Expect brighter, smoother skin when you wake.

Drunk Elephant T.L.C. Sukari Babyfacial 25% AHA + 2% BHA Mask

If you like to feel a product working, you'll positive love this mask. Like an AHA/BHA facial in a bottle, it resurfaces skin to reveal greater clarity and improved skin tone.

Drunk Elephant C-Firma Day Serum

This vitamin C day serum is packed with antioxidants to protect skin from urban aggressors.

Glossier Solution

A liquid exfoliator that you apply a bit like toner, it buffs away dead dulling skin with a single swipe.

Mario Badescu Drying Lotion

We know, we know, even supermodels get spots. This cult zit lotion contains salicylic acid, sulfur, and zinc oxide to dry up blemishes - fast.

Augustinus Bader The Rich Cream

The brainchild of a stem cell scientist no less, this overnight treatment uses amino acids and vitamins to re-energise cells to repair damage more effectively.

Original post:
Heidi Klum loves to pamper her skin with goodies from Drunk Elephant and Glossier - Woman & Home

Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform – PRNewswire

CHICAGO, Feb. 2, 2021 /PRNewswire/ -- Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence, today announced the launch of CiRC Biosciences, a cell therapy company developing treatments for serious diseases with high, unmet needs with an initial focus on the eye.

"The addition of CiRC Biosciences to our portfolio builds upon our cell and gene therapy platform, an area that has tremendous potential to address serious genetic diseases," said Jeff Aronin, founder, chairman and chief executive officer of Paragon Biosciences. "CiRC Biosciences gives us the science to target retinal diseases that could lead to vision restoration with numerous other applications in the years ahead."

CiRC Biosciences is currently advancing pre-clinical development of chemically induced retinal cells for vision restoration in Geographic Atrophy Age-Related Macular Degeneration (Dry AMD), which is the most common cause of irreversible vision loss over the age of 65, and advanced Retinitis Pigmentosa (RP), a genetic disorder that causes tunnel vision and eventual blindness. There are no U.S. Food & Drug Administration (FDA) approved treatments to restore vision loss in Dry AMD or RP.

The company's novel mechanism of action is designed for direct chemical conversion of fibroblasts into other cell types using a cocktail of small molecules in an 11-day chemical conversion process. Pre-clinical studies have shown efficacy in blind mice that demonstrated vision restoration. CiRC Biosciences has provisional patent applications to protect its platform.

"Our technology transforms ordinary skin cells into specialized retinal cells using a cocktail of small molecules," said Sai Chavala, M.D., co-founder and chief scientific officer of CiRC Biosciences. "This process is potentially safer, quicker, more cost effective and easier to manufacturer than using traditional stem cells. Working with Paragon Biosciences to build and advance CiRC Biosciences provides us the opportunity to efficiently progress this technology through research and development stages.

CiRC Biosciences first reported its discovery in the highly respected scientific journal Nature (April 15, 2020). A recently published New England Journal of Medicine article (Nov. 5, 2020)discussed CiRC's technology of using chemically induced cells to restore retinal function. The article concluded, "The new and emerging strategies for the rescue, regeneration, and replacement of photoreceptors suggest a bright future in the fight to preserve and restore vision in blinding eye diseases."

The abstract in Nature is available here: https://www.nature.com/articles/s41586-020-2201-4

Access to the NEJM article is available here: https://www.nejm.org/doi/full/10.1056/NEJMcibr2027602

About CiRC Biosciences CiRC Biosciences is a privately held cell therapy company dedicated to developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Currently it is pre-clinical phase for Geographic Atrophy Age-Related Macular Degeneration (Dry AMD) and advanced Retinitis Pigmentosa (RP). CiRC Biosciences is a portfolio company of Paragon Biosciences. Visit our website: https://circbiosciences.com/.

About Paragon Biosciences Paragon is a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence. The company's current portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the replicable Paragon Innovation Capital model. Paragon stands at the intersection of human need, life science, and company creation. For more information, please visit https://paragonbiosci.com/.

Media Contact:

Evelyn M. O'Connor Paragon Biosciences 312-847-1335 [emailprotected]

SOURCE Paragon Biosciences

Home

Read the rest here:
Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform - PRNewswire

Amazon just slashed up to 60 percent off this top-rated skincare brand but only for today – Yahoo Sports

Yahoo Life is committed to finding you the best products at the best prices. We may receive a share from purchases made via links on this page. Pricing and availability are subject to change.

As we continue to stare down several more weeks of winter (or more, pending what Punxsutawney Phil determines in a few days), its more important now than ever to take care of our winter-worn skin and hair. And under quarantine where, lets face it, a lot of us have been skipping certain steps in our self-care routines, having the kind of products that can not only protect but help restore some neglected areas is all the more important.

You (and your skin) are in luck: M3 Naturals has a wide range of personal care products perfect to help you feel and look better with every scrub, lather and shampoo. And today only, you can get up to 60 percent off these Amazon best-sellers.

Whether youre looking to battle wrinkles, clear up your skin, or just treat yourself in the shower, make sure to grab these before the deal ends its only for today.

With over 13,000 five-star reviews, this salt scrub boasts a plethora of good-for-your-skin benefits, from detoxifying and clearing to anti-aging, thanks to the potent blend of collagen and stem cells in the formula. Plus, natural ingredients like lychee fruit and sweet almond oil make it great for cleansing. Even better? Its made in the USA.

Shoppers cant get enough of the scrub, with one reviewer raving: Worth every penny! SO HAPPY I BOUGHT! adding, I love the relaxing feeling I get Scrubbing in the shower I instantly feel better.. all dead skin gone and left with super soft amazing looking skin!

Shop it: M3 Himalayan Salt Scrub, $14 (was $33), amazon.com

Battling crows feet and fine lines around your eyes? Just a few dabs once or twice a day can help reduce wrinkles, puffiness, or dark circles. With a combination of hyaluronic acid, stem calls and collagen, the M3 Naturals Eye Cream is designed to deliver results. Plus, it has nearly 2,400 five-star reviews!

Story continues

I have had bags and wrinkles under my eyes my entire life, one reviewer noted, I figured I would give this a try because of the reviews and such a difference! It was hard to capture the dark circles but those have lightened soooo much too. I am so excited and plan to buy another when I run out!

Shop it: M3 Eye Cream, $23 (was $29), amazon.com

Hair loss can affect both men and women, and while its certainly less stigmatized (thanks to Charlize Theron in Max Max for showing us that a cropped look can be mega stylish), we still want to be in control over our hairstyle, instead of letting our follicles decide for us. For those of us who want to give our scalp a push in the right direction, look no further than the M3 Hair Growth Shampoo. Its combination of collagen, biotin and argan oil help encourage thicker, healthier hair with a DHT blocker formula.

Hundreds of shoppers swear by this shampoo, with one sharing: My hair is very thin and I am only 39 years old...I have been using this only for a week and can already see a difference in the growth of my hair and also the thickness. It leaves your hair feeling so clean literally all day not like when I use other shampoo products. It smells pretty good actually and it has not left my hair greasy or anything. I also noticed I no longer have dandruff. I love this stuff.

Shop it: M3 Hair Growth Shampoo, $14 (was $18), amazon.com

This made-in-the-USA retinol is designed to be used on both your face and neck, and thanks to a potent infusion of collagen and stem cells, can tackle both fine lines and deep wrinkles. Its not just a wrinkle buster, either: The formula hydrates, brightens, and firms.

Shoppers agree, with one five-star reviewer happily reporting: This moisturizer is REALLY good! First, I love that it comes in a jar where you simply push down on the top and the lotion comes out. You get to control how much of the product actually comes out. (No more putting your fingers into a jar of lotion over and over.) Second, the lotion is thick, but not too thick. It is just the right consistency for a good facial moisturizer. It doesn't have a smell, and it doesn't take much product to cover your entire face and neck. I have only been using it for about a week, but I already completely love it!

Shop it: Retinol Moisturizer, $14 (was $18), amazon.com

For those of us who live and die by the drip of our Nespresso, were prone to believe coffee is nothing short of a miracle bean. But even the most devoted drinker will be blown away by how effective this Arabica Coffee Scrub is at cleansing and revitalizing skin. Not only does this scrub help promote smoother, healthier skin, but the subtle scent will help give you an extra bit of pep in your step. Looks like your favorite bean is just as good on your skin as it is in your cup.

Over 1,600 five-star shoppers found this scrub irresistible, with one reviewer who bought it as a gift admitting: This coffee scrub is fantastic! I bought it for my husband but I ended up using it, too! It really removes dead skin and doesn't leave your skin dry like other scrubs do. It is gentle enough for sensitive skin but works really well on rough patches of skin, too. It rinses clean and smells AMAZING.

Shop it: Arabica Coffee Scrub, $23 (was $29), amazon.com

The reviews quoted above reflect the most recent versions at the time of publication.

Read More from Yahoo Lifestyle:

Follow us on Instagram, Facebook, Twitter, and Pinterest for nonstop inspiration delivered fresh to your feed, every day

Want daily pop culture news delivered to your inbox? Sign up here for Yahoo Entertainment & Lifestyle's newsletter.

Continue reading here:
Amazon just slashed up to 60 percent off this top-rated skincare brand but only for today - Yahoo Sports

Valentina Greco Receives the 2021 ISSCR Momentum Award < Yale School of Medicine – Yale School of Medicine

The International Society for Stem Cell Research (ISSCR) will present this years ISSCR Momentum Award to Valentina Greco, PhD, Carolyn Walch Slayman Professor of Genetics and member of the Yale Stem Cell Center. The prize recognizes the exceptional achievements of an investigator whose innovative research has established a major area of stem cell-related research with a strong trajectory for future success. Greco will present her science during a special lecture on June 25 during ISSCR 2021 Virtual, the worlds leading meeting of global innovators in stem cell science and regenerative medicine.

Studies from Grecos lab are redefining scientific understanding of the complex mechanisms that organize and regulate the skin stem cell niche and the behavior of normal and mutant cells in the epidermis under physiologic challenge and with aging. Her groups body of work exploring cell biology in vivo determined that the niche, rather than the stem cells, are required for tissue growth, that location in the niche dictates stem cell fate, that the niche exploits stem cell plasticity to maintain homeostasis, and that homeostatic correction battles disease emergence. These breakthroughs pave the way for new concepts in mammalian regenerative biology.

Valentina is a wonderful ambassador for the stem cell community and in particular for young, female scientists in our field, said Christine Mummery, PhD, ISSCRs president. She has a confidence and skill to pursue bold new ideas. Not only is she a pioneer in live cell imaging, but she also has made multiple important discoveries regarding the mechanisms that regulate epithelial stem cell function. We are honored to recognize Valentina for her momentous achievements.

Beyond her creativity and scientific talent, Greco has shown great leadership. She is deliberate in her commitment to career development and the training of young faculty and her lab members, and brings tremendous enthusiasm to her work. Throughout her career, Greco has sought out new ways to enhance her effectiveness as a mentor by pursuing education from others, thereby establishing a strong foundation for making fundamental scientific discoveries in partnership with her lab members. She shared her perspectives and experiences as a woman and an immigrant working in science in Stem Cell Reports, Women in Stem Cell Science, Part 1.

My lab and I are honored to be recognized with this award, Greco said. Our science is inspired by the previous insights of incredible scientists that have paved the way for our contributions including the inspiring work of Cristina Lo Celso, David Scadden, Charles Lin, and Shosei Yoshida and their pioneering live imaging of mammalian stem cells in blood regeneration and spermatogenesis.

Greco was also awarded the ISSCR Dr. Susan Lim Outstanding Young Investigator Award in 2014.

Submitted by Robert Forman on January 25, 2021

See original here:
Valentina Greco Receives the 2021 ISSCR Momentum Award < Yale School of Medicine - Yale School of Medicine

Love Your Skin: What Is SPF And Why Is It Important? – Yahoo Movies Canada

GlobeNewswire

Fast-Growing U.S. Region Now Served by EPCORPHOENIX, Jan. 29, 2021 (GLOBE NEWSWIRE) -- EPCOR Water Arizona Inc., a subsidiary of EPCOR USA Inc. (EPCOR USA), has acquired the assets and operations of Johnson Utilities LLC. (Johnson Utilities), making EPCOR USA the water and wastewater service provider for one of the fastest-growing regions in the United States. Regulatory approval for the transfer of ownership was received from the Arizona Corporation Commission (ACC) on December 22, 2020. The financial transaction and transfer of ownership from Johnson Utilities to EPCOR was completed January 29, 2021. Recognizing the potential of the San Tan Valley, George Johnson founded Johnson Utilities in 1997. Under George Johnsons ownership of Johnson Utilities, the area experienced significant growth. Now known as the San Tan water and wastewater districts, EPCORs newest service areas are located just southeast of the greater metropolitan Phoenix area and anchor the Arizona Sun Corridor connecting the Phoenix and Tucson metropolitan areas, one of the most desirable growth corridors in the country. The 160-square-mile service area serves approximately 29,450 water and 40,160 wastewater customers in the communities of Florence, Queen Creek and unincorporated San Tan Valley in Pinal County. Were honored to be part of these vibrant communities where values that are important to EPCOR family and community are both the foundation and the future. We look forward to being an active community partner and bringing the kind of investment that is essential for job opportunities and the regions strong long-term economic outlook, said Joe Gysel, President of EPCOR USA. The ACC appointed EPCOR Interim Manager of Johnson Utilities in August 2018 and the company has worked to enhance service and reliability, address public health issues, and significantly improve customer satisfaction. More than $138 million in infrastructure improvements are still necessary over the next three years, including the construction of a new treatment facility and the expansion of another. This is the beginning of a new chapter. We are fully committed to bringing these customers safe, reliable service that is consistent with customer expectations, our brand and company values and were eager to get started, Gysel said. For further information, please contact: Rebecca StenholmDirector, Public & Government AffairsEPCOR USAO 623.445.2424 | C 602.390.5662 | rstenholm@epcor.com About EPCOR USAHeadquartered in Phoenix, Arizona, EPCOR USAs wholly owned subsidiaries build, own and operate water and wastewater and natural gas facilities and infrastructure in the southwestern United States. EPCOR USA is among the largest private water utilities in the Southwest and the largest in Arizona, providing water, wastewater, wholesale water and natural gas services to approximately 780,000 people across 42 communities and 18 counties in Arizona, New Mexico and Texas. About EPCOR Utilities Inc.EPCOR, through its wholly owned subsidiaries, builds, owns and operates electrical, natural gas and water transmission and distribution networks, water and wastewater treatment facilities, sanitary and stormwater systems, and infrastructure in Canada and the United States. The Company also provides electricity, natural gas and water products and services to residential and commercial customers. EPCOR, headquartered in Edmonton, is an Alberta Top 75 employer.

Link:
Love Your Skin: What Is SPF And Why Is It Important? - Yahoo Movies Canada

ToolGen ties up with 3D bioprinting company to apply induced pluripotent stem cells to gene correction – Aju Business Daily

[Courtesy of ToolGen]

SEOUL --ToolGen, a South Korean developer of genome editing technology, tied up with T&R Biofab, a 3D bioprinting company, to cooperate in applying induced pluripotent stem cells to gene correction. ToolGen has original technology related to third-generation gene scissors to cut out genetic information in cells.

Induced pluripotent stem cells (iPSCs) are derived from skin or blood cells that have been reprogrammed back into an embryonic-like pluripotent state that enables the development of an unlimited source of any type of human cell needed for therapeutic purposes. iPSCs can be derived directly from adult tissues and bypass the need for embryos.

ToolGen signed a memorandum of understanding T&R Biofab, which prints human organs and tissues for clinical transplantation, to develop and utilize cells that combine iPSCs and gene calibration technologies. "Inductive pluripotent stem cells are an ideal platform for developing gene correction therapy because they can be segmented into various cells," said ToolGen co-CEO Kim Young-ho.

ToolGen has partnered with VivaZome Therapeutics, an Australian biotech company, to develop therapies based on exosomes which are recognized for their critical role in cell-to-cell communication and transportation. The market for exosome therapeutics has been growing rapidly, and many life science companies have launched tools and systems to support exosome research.

Read the rest here:
ToolGen ties up with 3D bioprinting company to apply induced pluripotent stem cells to gene correction - Aju Business Daily

Opdivo Side Effects: What They Are and How to Manage Them – Healthline

If you have cancer and your doctor recommends Opdivo to treat it, you may be wondering what side effects this drug might cause.

Opdivo (nivolumab) is a brand-name prescription medication used in adults to treat certain types of cancer. These include specific forms of bladder, colorectal, and esophageal cancer, as well as several other cancer types. Its also used in some children to treat colorectal cancer.

Opdivo is a biologic drug (a type of drug made from living cells). Specifically, its an immunotherapy treatment, which means it can cause side effects involving your immune system. Its given as an intravenous infusion (an injection into a vein thats given over a period of time). For more information about Opdivo, see this in-depth article.

Opdivo may be a long-term cancer treatment. Your doctor will decide the length of your treatment based on various factors, including what side effects you experience.

Read on to learn more about the possible mild and serious side effects of Opdivo.

Like all drugs, Opdivo may cause side effects in some people.

The more common side effects of Opdivo include:

For more information about rash as well as muscle, bone, and joint pain, see the Side effects explained section below.

Certain side effects may be more common if other cancer drugs, such as ipilimumab (Yervoy), are part of your treatment plan. You may have a higher risk for certain side effects depending on the type of cancer you have.

Talk with your doctor about your risk for side effects, given your specific treatment plan. Also tell them about any side effect symptoms you may have.

Learn more about Opdivos side effects in the next sections.

You may experience mild side effects with Opdivo, such as:

For more information about muscle, bone, and joint pain, see the Side effects explained section below.

Opdivo may cause mild side effects other than the ones listed above. See the Opdivo Medication Guide for details.

Opdivos mild side effects should be manageable, and theyll likely go away during your treatment. But some could also be signs of more serious side effects.

If any side effects bother you, get worse, or dont go away, talk with your doctor or pharmacist. Try to keep all of your appointments to get Opdivo unless your doctor stops your treatment.

Opdivo may cause serious side effects. While these are generally rare, some people may be at higher risk for certain serious side effects. For example, your risk for some side effects may increase if youre receiving both Opdivo and other drugs for your cancer.

Call your doctor right away if youre having any new or worsening symptoms. If your symptoms feel life threatening, call 911 or get emergency medical care right away.

Serious side effects can include:

For more information on hepatitis, type 1 diabetes, and allergic reaction, see the Side effects explained section below.

Talk with your doctor about your risk for serious side effects. Also let them know about any concerns you may have.

Get answers to some frequently asked questions about Opdivos side effects.

No, Opdivo shouldnt cause confusion. In clinical studies of Opdivo, confusion wasnt a reported side effect.

However, confusion may be a symptom of rare, serious side effects of Opdivo, such as:

Also, Opdivo can cause hyponatremia (low blood sodium levels). Confusion is a symptom of this condition, which was a common side effect in certain clinical studies of Opdivo.

If youre feeling disoriented or having trouble thinking clearly during Opdivo treatment, contact your doctor right away.

In clinical studies of Opdivo as a melanoma treatment, reported side effects were similar to those researchers found when looking at the drug to treat other cancers.

However, Opdivo isnt always used alone to treat melanoma. The risk of side effects may differ depending on your treatment plan. For more information, see the Opdivo Medication Guide.

If youre receiving Opdivo infusions to treat melanoma, ask your doctor about your side effect risks.

Side effects with Opdivo can happen at any time, including after stopping treatment.

For example, severe reactions have happened during Opdivo infusions. However, these are rare compared with mild or moderate infusion-related reactions. Some people have had reactions within 2 days after their infusion, although these are rare as well.

Opdivo may cause your immune system to attack healthy tissues or organs. This can happen anytime during or after stopping Opdivo treatment.

Symptoms of a severe reaction that may happen during an Opdivo infusion can include:

If you have these or other symptoms during an Opdivo infusion, immediately tell the healthcare provider who is giving you the infusion.

Though rare, people have had reactions up to 2 days after their infusion. You should watch for any new or bothersome symptoms on the days between your infusions, too.

If you have a severe reaction, your healthcare provider may stop your Opdivo infusion. If you have a mild or moderate reaction during your infusion, they may slow the rate of infusion or pause it to help manage your symptoms.

Yes, it can. For example, Opdivo treatment could increase your risk for pneumonia. Pneumonia is a serious infection of the air sacs in one or both of your lungs.

In clinical studies for certain cancers, pneumonia was one of the more common serious reactions when Opdivo was used alone or with the cancer drug ipilimumab (Yervoy).

In clinical studies for certain cancers, rare but fatal infections have also occurred when Opdivo was used alone or with other cancer drugs.

Upper respiratory tract infection, such as a cold, is a common side effect of Opdivo. Though upper respiratory tract infections arent usually serious, they can lead to secondary infections such as pneumonia.

See your doctor if you have any infection symptoms such as a cough, shortness of breath, or fever.

Learn more about some of the side effects Opdivo may cause.

You may have painful joints from treatment with Opdivo. Joint pain is a common side effect of the drug.

Muscle, back, and bone pain are also common side effects of Opdivo.

Opdivo can cause your immune system to attack healthy tissues, even after youve stopped the drug. This can happen to any part of your body, including your joints. Rarely, arthritis (swelling in your joints) has occurred with Opdivo treatment.

If youre experiencing pain in your joints or other areas of your body during or after Opdivo treatment, talk with your doctor. They can check your symptoms and suggest ways you can manage them.

For mild joint pain, they may recommend you take an over-the-counter pain reliever, such as ibuprofen (Advil or Motrin). They may also suggest applying ice packs or warm compresses to your joints.

Rash is a common side effect of Opdivo.

In rare cases, Opdivo may cause a severe skin reaction, such as Stevens-Johnson syndrome. It may also result in allergic reactions, which may be mild or serious. Rash can be a symptom of both of these reactions.

During and after Opdivo treatment, contact your doctor if you have a rash that bothers you, gets worse, or doesnt go away. Get emergency medical care right away if you have blisters, peeling skin, or rash accompanied by fever, swelling, or trouble breathing. These could be signs of a severe, life threatening reaction.

If your symptoms are mild to moderate, your doctor may suggest that you manage them with a topical cream or ointment, such as hydrocortisone cream.

If youre having a severe skin reaction, your healthcare provider will pause or permanently stop your Opdivo infusions. Theyll manage the reaction with corticosteroids, such as prednisone, or other immune-suppressing drugs.

Though rare, Opdivo treatment may cause your immune system to attack healthy tissues, including your liver. When this happens, it can cause inflammation (swelling and damage) of your liver known as hepatitis.

This side effect may be more likely to happen if your treatment plan includes both Opdivo and the cancer drug ipilimumab (Yervoy).

If you have hepatitis from Opdivo treatment, your healthcare provider will pause or permanently stop your infusions. Theyll manage the condition with a corticosteroid drug, such as prednisone. In some cases, you may need to take another immune-suppressing drug.

During and after stopping Opdivo treatment, tell your doctor if you have any symptoms of hepatitis, such as:

Rarely, Opdivo may cause type 1 diabetes. With type 1 diabetes, your blood glucose (sugar) level becomes too high because your pancreas isnt releasing insulin. If untreated, this can lead to serious complications. An example is diabetic ketoacidosis (high levels of blood acids called ketones), which can be fatal.

Your doctor may check your blood glucose level while youre getting Opdivo. During and after your treatment, watch for any diabetes or ketoacidosis symptoms, such as:

Remember, high blood glucose can cause severe complications. If you have any of the symptoms listed above, see your doctor or get medical care right away.

Like most drugs, Opdivo can cause an allergic reaction in some people. Symptoms can be mild or serious and can include:

For mild symptoms of an allergic reaction, such as a mild skin rash or itching, call your doctor right away. They may suggest an over-the-counter oral antihistamine, such as diphenhydramine (Benadryl), or a topical product, like hydrocortisone cream, to manage your allergic reaction.

If your doctor confirms you had a mild allergic reaction to Opdivo, theyll decide if you should continue receiving this drug.

If you have symptoms of a severe allergic reaction, such as swelling or trouble breathing, call 911 or your local emergency number right away. These symptoms could be life threatening and require immediate medical care.

If your doctor confirms you had a serious allergic reaction to Opdivo, theyll stop your Opdivo treatment and decide if another cancer treatment is right for you.

During your Opdivo treatment, consider keeping notes on any side effects youre having. Then, you can share this information with your doctor. This is especially helpful to do when you first start taking new drugs or using a combination of treatments.

Your side effect notes can include things like:

Sharing such notes with your doctor will help your doctor learn more about how Opdivo affects you. Your doctor can also use this information to adjust your treatment plan if needed.

Opdivo may not be right for you if you have certain medical conditions or other factors that affect your health. Talk with your doctor about your health history before starting Opdivo. Factors to consider include those mentioned below.

Stem cell or organ transplant. Opdivo treatment before or after an allogenic hematopoietic stem cell transplant (transplant of blood-forming cells from a genetic match) could cause serious or fatal problems.

If youre planning a stem cell transplant or have had one, talk with your doctor about the safety of Opdivo treatment. Also tell your doctor if youve received an organ transplant.

Allergic reaction. If youve had an allergic reaction to Opdivo or any of its ingredients, Opdivo shouldnt be part of your cancer treatment. Ask your doctor what other medications are better options for you.

Immune system problems. With Opdivo treatment, your immune system may attack healthy tissues.

Before starting Opdivo, tell your doctor if you have an autoimmune or inflammatory condition, such as Crohns disease, ulcerative colitis, or lupus. Tell them even if your condition is in remission (times when youre symptom-free).

History of chest radiation. Opdivo may cause a serious side effect of the lungs called pneumonitis. Your risk for pneumonitis may be higher if youve had radiation treatment to your chest.

Before starting Opdivo, tell your doctor about any past chest radiation treatments youve had and if youve received other drugs similar to Opdivo.

Nervous system problems. In rare cases, Opdivo treatment may cause your immune system to attack your nervous system, including your brain, spinal cord, or nerves.

Before starting Opdivo, tell your doctor if youve had a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barr syndrome.

Opdivo doesnt interact with alcohol.

However, alcohol can harm your liver. In rare cases, Opdivo can cause inflammation (swelling and damage) of your liver known as hepatitis. Opdivo can be used to treat some liver cancers.

Ask your doctor if its safe to consume alcohol while being treated with Opdivo.

Its unsafe to be treated with Opdivo during pregnancy. If youre able to become pregnant, youll need to get a pregnancy test before starting Opdivo to make sure youre not pregnant.

Youll also need to use effective birth control during treatment and for at least 5 months after your last infusion.

Opdivos manufacturer hasnt given recommendations about contraception for people taking Opdivo who have a partner who can become pregnant. If you have questions or concerns about this, talk with your doctor.

Its unknown if Opdivo is safe to use while breastfeeding. You shouldnt breastfeed during Opdivo treatment or for at least 5 months after your last infusion.

Before starting Opdivo, talk with your doctor about safe ways to feed your child.

Opdivo may help treat your type of cancer. At the same time, it can put you at risk for rare but serious side effects. However, most common symptoms of Opdivo are mild or manageable.

If youre wondering about Opdivos side effects, talk with your doctor or pharmacist. Ask questions to get the answers you need to feel confident about your cancer treatment. Here are a few to get you started:

My doctor said thyroid problems are possible serious side effects of Opdivo. What symptoms should I watch for?

Opdivo may cause your immune system to attack your thyroid gland, resulting in thyroiditis (inflammation of the thyroid gland). Though thyroiditis isnt usually serious, it can lead to hypothyroidism (low thyroid levels) or hyperthyroidism (high thyroid levels).

Hypothyroidism may happen more often, especially when Opdivo is used with ipilimumab (Yervoy).

Symptoms of hypothyroidism include increased weight, fatigue (lack of energy), and feeling cold. They also include a slow heart rate, depression, and a puffy face.

Symptoms of hyperthyroidism include a fast heart rate, high blood pressure, shaking hands, and trouble sleeping.

Call your doctor if you have any of the above symptoms. They may pause or stop your Opdivo treatment depending on how severe the side effect is. Your doctor may also recommend that you take other medication to treat your hypothyroidism or hyperthyroidism.

Read more here:
Opdivo Side Effects: What They Are and How to Manage Them - Healthline

Why Hair Goes Gray, and How to Cover It If You Want To – NewBeauty Magazine

Lets get into the science behind it: As hair is being formed, melanocytes inject pigment into keratinocytesthe cells containing keratinwhich is the protein making up hair, skin and nails, says Wayne, NJ plastic surgeon and hair specialist Jeffrey B. Wise, MD. Over time, melanocytes continue to inject pigment into the hairs keratin, which is where hair gets its color. In the aging process, melanocytes slow down and eventually stop secreting melanin, which causes a lack of pigment, and the hair turns gray.

According to Chicago dermatologist Dr. Quenby Erickson, going gray is programmed in our genetic code, which means we can get clues as to how extensively and when it will happen by looking at our parents. However, a 2020 study published in Science Daily shows there may also be a link between stress and gray hair. When testing on mice, researchers found that the type of nerve involved in the fight-or-flight response causes permanent damage to the pigment-regenerating stem cells in the hair follicle. The study makes perfect sense, says Dr. Wise. Stress is a huge factor in premature aging, as well as hair thinning. Naturally, it should also affect hair graying as well. There is also a lot of evidence that shows smoking cigarettes plays a role in making hair go gray earlier.

Color isnt always the only factor either; textural changes can ensue as well. Some people are blessed with gorgeous gray hair, but for most of us, the gray is accompanied with thinning and rougher texture that leave our hair finer and harder to style, Dr. Erickson says. There are no proven ways to prevent hair from turning gray, but both Drs. Erickson and Wise have seen some promising results from platelet-rich plasma (PRP) injections. Because these treatments are aimed at waking up your own stem cells, they could potentially reinvigorate melanocyte production as well, explains Dr. Wise. We have seen growth of darker, thicker hairs on some of our stem cell therapy patients, even though the original goal was to combat thinning. Treatment results are dependent on the patients individual conditions, so realistic expectations should be set by your doctor.

Celebrity colorists Chad Kenyon and Rita Hazan say none of their clients embraced their grays during quarantine, or they tried, but caved eventually. For those in camp cover them up, topical dyes and root concealers can help camouflage. The process to cover gray hair is the same on both blonds and darker shades, but my clients with lighter hair can go longer in between touch-ups because gray hairs blend with blond hairs more easily, says Kenyon. Celebrity colorist Aura Friedman often suggests adding a darker pepper tone to silver hair for people who feel more comfortable being darker, but dont want the two-, three- or four-week regrowth touch-up thats needed.

For those who want to permanently cover their grays at home, Nikki Lee, celebrity colorist and cofounder of Nine Zero One Salon, recommends Garnier Nutrisse Nourishing Color Creme ($8). There are more than 75 shades and you can easily find your match using a virtual shade selector, she says. If DIY color makes you nervous, temporary root sprays are great to use in between salon appointments.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

See the rest here:
Why Hair Goes Gray, and How to Cover It If You Want To - NewBeauty Magazine

Studies Indicating T-Cells May Be Needed For Long-Term Protection From The SARS-Cov-2 Virus – PRNewswire

PALM BEACH, Fla., Jan. 28, 2021 /PRNewswire/ -- According to the National Institutes of Health (NIH), the tide in the global fight against COVID-19, the disease caused by the SARS-CoV-2 virus, may soon begin to turn. Last month, three pharmaceutical companies announced promising results from vaccine trials. Countries around the world are now poised to begin the largest mass vaccination campaigns since the 1950s. Researchers led by Dr. Dan Barouch of Beth Israel Deaconess Medical Center used monkeys to look at levels of antibodies and immune cells required to prevent reinfection with the virus. NIH said some questions remainabout what types and amounts of immune system components are needed to produce long-term immunity against SARS-CoV-2. This information would be valuable both for tracking the effectiveness of vaccines and designing new ones in the future. It said that This finding suggests that T cells are needed for long-term protection from the virus. "Antibodies alone can protect, including at relatively low levels, but T cells are also helpful if antibody levels are insufficient," Barouch says. "Such knowledge will be important in the development of next generation vaccines, antibody-based therapeutics, and public health strategies for COVID-19."Active biotech companies in the Covid-19 developments this week include Sorrento Therapeutics, Inc. (NASDAQ: SRNE), BioVaxys Technology Corp. (OTCPK: LMNGF) (CSE: BIOV), INOVIO (NASDAQ: INO), CytoDyn Inc. (OTCQB: CYDY), Novavax, Inc. (NASDAQ: NVAX).

BMJ. Com reportedon a similar test but humans were the patients here, to find out how long the T Cells last after an infection. The results were that Robust cellular immunity persists for at least for six months after even mild or asymptomatic SARS-CoV-2 infection, research has shown. The study of 100 people showed that all had a cellular immune response against SARS-CoV-2 six months after infection although the size of response was 50% higher in those who had experienced symptomatic disease. There has been concern that the cellular immune response following covid-19 infection may not be sustained. "This data is reassuring," lead study author Paul Moss, from the University of Birmingham, told a Science Media Centre briefing on 2 November. "However, it does not mean that people cannot be re-infected. We need to have much larger population studies to show that." Moss also added that the findings "can't be taken as confirmation that an 'immunity passport' would be feasible."

BioVaxys Technology Corp. (OTCPK: LMNGF) (CSE: BIOV.CNQ) BREAKING NEWS: COVID-T CLINICAL DEVELOPMENT PROGRAM INITIATED REGULATORY ADVISORY GROUP ENGAGED - BioVaxys Technology Corp. ("BioVaxys") is pleased to announce that it has initiated the clinical development program for Covid-T, the Company's novel diagnostic platform for detecting T-cell activity. The US Food and Drug Administration ("FDA") has tentatively agreed to permit that BioVaxys can file for a pre-Emergency Use Authorization ("EUA") for Covid-T. Under an EUA, FDA may allow the use of unapproved medical products, or unapproved uses of approved medical products in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when certain statutory criteria have been met, including that there are no adequate, approved, and available alternatives.

Covid-T addresses an unmet need for a low-cost, easy-to-administer, and accurate tool to test for the presence of T-cells which may offer lasting protection against SARS-CoV-2.

It is believed that detection of T-cells can potentially identify safe and/or at-risk populations. Covid-T also provides an ability to evaluate the effectiveness of any SARS-CoV-2 vaccine candidate in stimulating T-cell immunity. Mass availability of Covid-T would complement antibody testing and various public health risk mitigation strategies.

James Passin, CEO of BioVaxys, stated, "We believe that our low cost, scalable, easy-to-administer test for T cell immunity to SARS-CoV-2 may help solve the urgent global public health crisis of prioritizing the distribution of Covid-19 vaccines; we look forward to rapidly advancing Covid-T towards commercialization."Current methods of measuring T-cell immunity require drawing blood from the test subject, followed by a time-consuming and expensive analysis of the blood sample at laboratories possessing specialized equipment.

Covid-T is based on the well-established concept of Delayed Type Hypersensitivity ("DTH"), the oldest and most reliable test of human T lymphocyte function. The process involves an intradermal "skin prick" of an immunogenic composition of the SARS-CoV-2 S-protein, where an inflammatory response develops 24-72 hours after skin exposure to the s-spike antigen.

BioVaxys anticipates that once clinical testing is complete, Covid-T would have the potential for detecting differences in T-cell responses between the original SARS-CoVC-2 virus and the two new strains of SARS-Cov-2 the had originally been identified in the UK and South Africa---B.1.1.7 and 501Y.V2, respectively--- but which are spreading worldwide.

"Although our vaccine programs are of major importance to us, Covid-T is a priority for BioVaxys, especially given the unmet need for such a simple, disposable, and accurate tool to test for the presence of T-cells against SARS-CoV-2," says BioVaxys President and Chief Operating Officer Ken Kovan.BioVaxys has prepared the clinical development plan for Covid-T, and engaged global regulatory advisory group Rio Pharmaceutical Services ("RPS") of Bridgewater, NJ, to provide strategic regulatory guidance, prepare an FDA pre-submission guidance package, recommend regulatory pathway, and support BioVaxys on the registration filing.

RPS has provided pharmaceutical and medical-device advisory services across the entire drug, biologic and device development and approval spectrum of the pharmaceutical industry since 2000.Collectively, the RPS team of pharmaceutical industry executives offers nearly 150 years of experience in providing advice and support services for medical, scientific, clinical-trial and regulatory issues to clients including a majority of Fortune 500 pharmaceutical companies. Read this full release and more news for BioVaxys Technology at: https://www.financialnewsmedia.com/news-biov/

Other recent developments in the biotech industry include:

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) recently announced positive preliminary results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 106cells/kg. The primary objective is to evaluate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS. The secondary objective is to evaluate efficacy outcome variables to give guidance regarding the risk/benefit ratio in patients with COVID-19 respiratory distress.

The first three patients enrolled tolerated treatment well and improved rapidly. Each of the three patients was discharged from the hospital within a week of starting the patient's COVI-MSC infusions and two patients were discharged on the day of their last infusion. One of the patients had been in the hospital for three weeks, unable to be weaned from significant oxygen support, and another patient with uncontrolled diabetes had been discharged previously but had to be readmitted due to recurrent ARD. Each of the infusions were well-tolerated and no patient reported any infusion-related adverse events. A fourth patient is currently at the beginning of a course of treatment, with no safety issues following the patient's first infusion. Additional enrollment continues.

INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine"), an emerging biotech company with next-generation technology in vaccines, both preventive and therapeutic, recently announced that they have entered into a collaboration and license agreement for COVID-19 DNA vaccine candidate INO-4800.

Under the collaboration and license agreement, Advaccine will have the exclusive right to develop, manufacture and commercialize INO-4800 withinGreater China, inclusive of Mainland China,Hong Kong,Macao, andTaiwan. Advaccine will license its plasmid manufacturing process for use with INO-4800 and other INOVIO pipeline product candidates to INOVIO with the right to sublicense to INOVIO's manufacturing partners. Additionally, Advaccine will provide its clinical data to INOVIO in support of INOVIO's global INO-4800 regulatory filings and INOVIO will provide its INO-4800 clinical data for Advaccine to incorporate into its marketing applications inGreater China. Advaccine will make to INOVIO an upfront payment of$3.0 millionas well as pay an aggregate of$108.0 millionupon the achievement of specified development and sales-based milestones for INO-4800 inGreater China. INOVIO will be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region withinGreater China.

CytoDyn Inc. (OTCQB: CYDY), a late-stage biotechnology company developing Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced this month a research manuscript submitted by Nicholas J. Agresti, M.D. has been accepted for publication in the Journal of Translational Autoimmunity. Dr. Agresti's research findings were based on four critically ill COVID-19 patients treated with leronlimab under eIND.

The manuscript Ms. No. JTAUTO-D-20-00043R1 is entitled "Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab."

Nicholas J. Agresti, M.D., stated, "We are very thankful with the clinical outcomes for these patients and are honored by the acceptance of our research for publication. We hope this work will continue to advance research to understand how to effectively mitigate the effects of COVID-19."

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, recently announced that it has finalized an agreement with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, the company's recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option for up to an additional 24 million doses. NVX-CoV2373 is currently in Phase 3 clinical development for the prevention of COVID-19.

"We thank the Government of Canada for their confidence in our program and ongoing partnership in the regulatory review and delivery of a safe, effective COVID-19 vaccine for the citizens of Canada," said John J. Trizzino, Chief Commercial Officer and Chief Business Officer, Novavax. "Novavax is proud to play our part in working tirelessly together with governments, scientists, regulators and others in the global effort to put an end to the pandemic."

The company expects to supply NVX-CoV2373 to Canada beginning as early as the second quarter of 2021, following authorization by Canada's regulatory agency.

DISCLAIMER:FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers.Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.For current services performed FNM has been compensated forty nine hundred dollars for news coverage of the current press releases issued by BioVaxys Technology Corp. by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:[emailprotected]+1(561)325-8757

SOURCE FinancialNewsMedia.com

Read more from the original source:
Studies Indicating T-Cells May Be Needed For Long-Term Protection From The SARS-Cov-2 Virus - PRNewswire

How to Treat a Wounded Manatee – The New York Times

Unfortunately, there arent too many manatees that dont have a wound, says Jon (JP) Peterson, vice president of zoological operations at SeaWorld in Orlando, Fla. Peterson oversees the rescue team, a group of wildlife veterinarians and animal specialists who travel the coastal waterways of the Southeast providing emergency medicine to wild animals, including injured, cold and orphaned manatees. Boats are the most common cause of wounds: Sharp skegs and propellers scrape along the animals backs and flanks, leaving behind everything from minor scratches to much more severe lacerations like those Peterson calls sucking chest wounds.

Assess the cut and nearby tissue. Gray is bad, Peterson says. You want pink. If you see dark gray or brown, blood, pus or smell a pungent odor, there is usually infection. A manatees outer skin is tough, like an elephants hide, and prone to close up quickly. Clean, flush and scrub the wound with a sterile solution like chlorhexidine until youve removed the necrotic tissue (you may need to cut it out). To accelerate healing, Petersons team uses antibiotics, cold-laser therapy and stem cells, as well as raw, unpasteurized honey. Use a tongue depressor and pack the honey into the wound, Peterson says. With its sticky, antibacterial properties, honey stays put, even underwater.

Dont underestimate the strength of these animals. Theyre one ball of muscle, Peterson says. Dolphins and whales make less challenging patients. Release healed manatees back into the wild. Of course, unless youre trained and permitted by the U.S. Fish and Wildlife Service, you should not handle manatees at all. Mistreating them is illegal and can result in a fine and prison time. In 1967, only a few hundred manatees remained in Florida when they were listed among the first class of endangered species under the Endangered Species Act. Researchers now estimate the population at 6,300, most with crisscrossing bright white scars across their bodies. In fact, scarring is so prevalent that scientists use scar patterns to identify individual manatees during aerial surveys. You can look down from an airplane and see, Oh, look, theres so-and-so, Peterson says.

View original post here:
How to Treat a Wounded Manatee - The New York Times

Research finds new proof about the systems controlling skin repair and regeneration – Microbioz India

As the air continues to dry and temperatures drop, the yearly battle against dry hands and skin has officially begun. New research from Northwestern University has discovered new evidence deep within the skin about the mechanisms controlling skin renewal and repair.

Skins barrier function gives it the unique ability to fight winter woes and keep water for our bodies. The outer layer of the skin, the skin, is constantly turning over to replace damaged or dead cells, creating new cells to reinforce the barrier function and heal damage. The gene regulatory mechanisms that control epidermis turnover remain incompletely understood.

Every month were covered with a new layer of the epidermis, said Northwesterns Xiaomin Bao, who headed the study. The next question is what does that procedure involve?

The newspaper will be published on Jan. 19 in the journal Nature Communications.

GeneticjunkThe scientific community has developed a wide breadth of knowledge about proteins, the workhorses of various cellular activities. Many mysteries remain about the nature of introns, non-coding segments of DNA that make up 24% of the human genome.

Regardless of the general belief that introns are nothing butgenetic junk, they actually play critical roles in modulating RNA transcription throughout a tissues lifespan. RNA transcription is the first step of gene expression, in which the data from DNA is copied into RNA, which is then subsequently used as a template for synthesizing proteins to drive the specific function of a cell.

Based on where transcription terminates within an intron or at the conclusion of a gene an epidermal stem cell will either remain a stem cell or become a specified cell barrier function. Bao said while its well-known that transcription ends at the end of a gene, her labs research found conflicting data.

Future research could have implications for carcinoma research.

Technology critical to the discovery of the phenomenonSkin cells are gaining popularity with researchers in part because of their regenerative properties and readiness to grow in cultures. This allows researchers to apply an assortment of state-of-the-art technologies. By growing skin cells and regenerating skin tissue in a petri dish, the Bao Lab can experiment with this fast-growing tissue to determine molecular mechanisms and regulatory elements within DNA.

Technology development is an integral driver that enabled us to uncover this new phenomenon, Bao said.

The group used a novel genomic technique that maps where transcription stops. The integration of proteomic approaches identified RNA-binding proteins which read specific regulatory sequences in the introns.

The team further leveraged CRISPR technologies to delete genomic sequences in the intron, which provided direct evidence demonstrating that the crucial roles of introns in modulating gene expression.

Before this study, mechanisms between introns to govern the switch between a skin stem cell and a terminally differential state (for example, a cell that participates in forming a skin barrier), were unknown. Most studies ignored introns, despite them accounting for 10 to 20 times more sequences than the protein-coding regions (exons) in the human genome.

The study demonstrates that different genes may involve different sets of RNA-binding proteins to recognize the regulatory sequences in their introns. These RNA-binding proteins help to mature RNAdecide whether to cut transcription early or dismiss termination sites within an intron during differentiation due to changes in protein availability.

We are only starting to appreciate the roles of the intron in human health and diseases, Bao said.

Results of this study could have broader impacts because, according to Bao, the procedures regulating skin cells are almost definitely not restricted to skin cells. Future research on other systems, including other epithelial tissues, will likely uncover similar patterns.

We are extremely hopeful that what weve found is the first step to knowing what we have ignored in the past, Bao said. My students also wish to know more about the RNA binding proteins which provide specificity in governing which site to use to terminate transcription.

Source:

Originally posted here:
Research finds new proof about the systems controlling skin repair and regeneration - Microbioz India

4 Doctors Reveal the Pros and Cons to Microneedling Treatments – NewBeauty Magazine

While the thought of dozens of tiny needles aimed directly at our faces sounds like a scare, microneedling may be worth it for the radiant skin it delivers. As with any trending procedure, it has its pros and consheres what four top doctors want you to know before scheduling an appointment.

It Opens Up the Skin BarrierMicroneedling creates little puncture sites in the skin, which allow for deeper product penetration, says Highland Park, IL plastic surgeon Steven P. Bloch, MD, who recommends combining the treatment with TCA peels that include hydrogen peroxide, exosomesthe healing, skin-calming growth factors derived from stem cellsor vitamins to stimulate collagen and elastin production. Applying medical-grade skin-care products after the procedure offers the best results because the skin will soak everything up much more effectively.

It Stimulates Collagen ProductionAs we age, our bodies produce less collagen (starting as early as our 20s), and therefore our skin begins to lose elasticity. However, Birmingham, AL dermatologist Corey Hartman, MD explains that microneedling promotes collagen production in our skin cells, helping it look as young as possible. Microneedling, which works on all skin types, administers small injuries to kick the bodys natural healing process into gear and rejuvenate the skin, he explains. Though there are only a few procedures in cosmetic dermatology that are truly preventive, microneedling delivers on the promise to stimulate fibroblasts, which synthesize the production of collagen.

ItCanBeEffectiveforTreatingMelasmaOne of the most common concerns women walk into our office with is melasma, says Grand Rapids, MI plastic surgeon Bradley Bengtson, MD. More often than not, melasma is not optimally treated with high-heat laser devices, so microneedling is a great tool to break up the pigment. The procedure banishes dark patches by allowing brightening creams and serums with ingredients like vitamin C to penetrate deep into the epidermal and dermal layers.

ItRequiresNoSkilltoUseAny Tom, Dick, Sally or Jane can buy a microneedling machine, set up a strip-mall shop and offer it to people, says Eagan, MN dermatologist Charles E. Crutchfield III, MD, who stresses that complications can arise if you dont visit a board-certified doctor for the treatment. Instead, he recommends an ablative laser, which also boosts collagen and tightens the skin with much more sophistication.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Read the original:
4 Doctors Reveal the Pros and Cons to Microneedling Treatments - NewBeauty Magazine

Here’s Why The Body Shop Is A Cult Brand to Know Plus The Best-Sellers To Buy – GLAMOUR UK

Body Shop stans, assemble! We have collated the best the brand has to offer to optimise your bathroom cabinet.

But before you start shopping, here are a few did you knows. This cruelty-free, British brand was the first international cosmetics brand to prohibit the use of ingredients tested on animals and one of the first to promote Fair Trade with third world countries. Earning its place as a household name over the past four decades plus a cult following, thanks to a diverse range of over 900 products, suitable for different skin tones and types and half of which are vegan.

For some insight, this Brighton-born beauty story dates back to 1976. It was founded by the iconic entrepreneur and human rights activist Dame Anita Roddick, pioneer to ethical consumerism, who wanted to create a high quality, revolutionary skincare range that would be a positive force in the beauty landscape. What differentiated Roddicks vision to other beauty giants was her desire to create the perfect harmony between quality, accessibility, environmental consciousness (starting out with refillable containers etc) and profit. That passion filtered through to employees - and the brand's ideology hasnt much changed along the years.

Helping disadvantaged communities is a brand priority and they have been sourcing their Community Fair Trade (CFT) shea butter from Tungteiya Womens Association in Northern Ghana since 1994. Where 640 women from 11 villages, handcraft shea butter using an 18-stage process of traditional techniques, successfully creating generational opportunities passed from mother to daughter. Their CFT handcrafted paper and gift packaging is also sustainably sourced from Kathmandu, Nepal.

A B Corp certified brand is amongst the 3,000 businesses worldwide to have the highest social and environmental standards for people and the planet. One focus is on using plant-based and recycled plastic (rather than oil-based plastics) and creating initiatives to aid consumers around the world to reuse, repurpose and recycle. In 2019, we reintroduced our pioneering refill scheme, a recycling programme and removed 21 tonnes of plastic from our gifts. says says Linda Campbell, Managing Director for the UK.

The ideals of The Body Shops founder had a direct impact on the direction of the brand. They havent shied away from supporting feminist movements, constantly raising the bar on ethical consciousness and fighting to empower girls and women across all demographics. The Body Shop have spent the last few years initiating and aligning with campaigns, most recently the Covid-19 response derived #IsolatedNotAlone campaign. With the objective of raising awareness on domestic abuse and providing potentially life-saving resources for survivors and bystanders at increased risk during lockdown measures." says Campbell.

If all this doesnt make you feel more passionate about the brand, we dont know what will. And that's before we even get the quality products at consumer friendly prices. But dont let the Body Shop name fool you though, as not only extensive bath and body sup, but skincare, haircare and vegan makeup.

If youre a lover of newness, you might want to investigate the latest drop, which includes Hemp Dry Body Oil, 14, and the Drops of Youth Bouncy Jelly Mist, 16. A gel-to-mist formula protect the skin from indoor and outdoor pollution as well as the effects of blue light from all the Zooming.

But the beauty giant is just as loved for its cult products, from the nourishing glow masks to their world famous body butters (which sell at a rate of one every three seconds). If you want to know what the hype is really about, here is a selection of the 10 bestselling products and why they deserve a spot in your bathroom cabinet.

See the rest here:
Here's Why The Body Shop Is A Cult Brand to Know Plus The Best-Sellers To Buy - GLAMOUR UK

Ohio State establishing national standards for ALS genetic testing, research and patient care | Ohio State Medical Center – Wexner Medical Center -…

Led by genetic counselor Jennifer Roggenbuck, MS, LGC, a one-year grant awarded by the ALS Association is funding Ohio States formal development of national clinical guidelines for ALS genetic testing that will be used by healthcare centers nationwide. We have cared for thousands of patients since opening our ALS/MND Clinic in the mid-1990s and have extensive experience with genetic testing, says Roggenbuck. We believe its extremely important to establish national testing standards, to ensure that all persons with ALS can benefit from genetic advances, and to fuel further research.

Genetic testing and counseling directly benefits our patients, explains clinic director Stephen J. Kolb, MD, PhD. Genetic characterization of our patients also opens the door to research opportunities. In addition to formal genetic counseling, our clinic has an ALS Clinical Research Coordinator who meets with every patient to explain our basic science and clinical trial opportunities and answer any related questions. Our patient partnerships are a key factor in the size and scope of our research program. Because Ohio State is now among the largest ALS research sites in the country, were regularly asked to participate in or lead high profile National Institutes of Health (NIH) and foundation studies.

A major focus of our program is to connect the individuals that we serve in clinic to the critical research efforts that are happening in laboratories here at Ohio State as well as those throughout the world. One example of this is the development of individualized models of disease, says Dr. Kolb. We and our collaborators are able to biopsy a persons skin cells and turn them into a type of stem cell that allow us to reproduce each patients exact ALS condition in the laboratory. We can then study the models to look for causes and develop therapies on a case-by-case basis.

The ALS/MND Multidisciplinary Clinic and Research Program is part of Ohio States Neurological Institute, with one of the largest neuromuscular centers in the country, so there is an established team of multidisciplinary experts to help each patient, even those with unusual or difficult symptoms. The ALS/MND program is led by Kolb, a physician-scientist, and in addition to the full-time research coordinator, he is joined by a clinical neurologist, genetic counselor, clinical nurse practitioner, social worker and nutritionist, as well as physical, occupational, respiratory and speech therapists. The Ohio State Department of Neurology is a member of NeuroNEXT: Network for Excellence in Neuroscience Clinical Trials and a contributing member to the Northeast ALS Consortium (NEALS).

Read feature stories

View post:
Ohio State establishing national standards for ALS genetic testing, research and patient care | Ohio State Medical Center - Wexner Medical Center -...

Plant Stem Cell Market- Growth Opportunities by Manufacturers, Regions, Type and Application; Trends Forecast to 2026 | Coherent Market Insights – The…

Global Plant Stem Cell Market 2020 by Company, Regions, Type and Application, Forecast to 2026

Plant stem cells are undifferentiated cells within the meristems of plants.Plantstem cellsserve as the origin of plant vitality as they maintain themselves and provide a steady supply ofprecursor cellsto form various tissues and organs in plants. Plant stem cells are characterized by two distinctive properties namely its ability to create differentiated celltypes and to self-renew such that the number of stem cells remain stable. The plant stem cell market focuses on this ability of plant cells and thus, processed extracts from the buds, roots and shoots are in high demand and are widely used for topical uses.

This report is an essential reference for those who look for detailed information on the Global Plant Stem Cell Market. The report covers data on global markets including historical and future trends for supply, market size, prices, trading, competition and value chain as well as Global major vendor information. In addition to the data part, the report also provides an overview of Plant Stem Cell market, including classification, application, manufacturing technology, industry chain analysis and the latest market dynamics.

Global Plant Stem Cell Market Research Reports provides information regarding market trends, competitive landscape, market analysis, cost structure, capacity, revenue, gross profit, business distribution and forecast 2024.

Plant Stem Cell Market was valued at xx million US$ in 2020 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2020-2025.

The Global Plant Stem Cell market is highly competitive and consists of a number of major manufacturers like Oriflame Holding AG, MyChelle Dermaceuticals, LLC, Natura Therapeutics Inc, Aidan Products LLC, Mibelle Biochemistry, Phyto Science SDN BHD, and Renature Skin Care Inc.

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/98

Scope of the Report:

The segmentation has been done on the basis of types, applications, technology, and users. Each segment has been further explained with the help of Table of Content, Tables and Figures. This breakdown of the market gives the readers an objective view of the global Plant Stem Cell market, which is essential to make sound investments. Both these assess the path the market is likely to take by factoring in strengths, weaknesses, opportunities, and threats.

This report also includes the overall and comprehensive study of the Plant Stem Cell market with all its aspects influencing the growth of the market. This report is an exhaustive quantitative analysis of the Plant Stem Cell industry and provides data for making strategies to increase the market growth and effectiveness.

The Global Plant Stem Cell market 2019 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Plant Stem Cell market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

In addition to this, regional analysis is conducted to identify the leading region and calculate its share in the global Plant Stem Cell market. Various factors positively impacting the growth of the Plant Stem Cell market in the leading region are also discussed in the report. The global Plant Stem Cell market is also segmented on the basis of types, end users, geography and other segments.

On the basis of geography, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/98

The major factors defined in this report are:

The study objectives of this report are:

To study and analyze the global Plant Stem Cell consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.

To understand the structure of Plant Stem Cell market by identifying its various subsegments.

Focuses on the key global Plant Stem Cell manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Plant Stem Cell with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Plant Stem Cell submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/98

Table of Content:

Chapter One: Industry Overview of Plant Stem Cell

Chapter Two: Manufacturing Cost Structure Analysis

Chapter Three: Development and Manufacturing Plants Analysis of Plant Stem Cell

Chapter Four: Key Figures of Major Manufacturers

Chapter Five: Plant Stem Cell Regional Market Analysis

Chapter Six: Plant Stem Cell Segment Market Analysis (by Type)

Chapter Seven: Plant Stem Cell Segment Market Analysis (by Application)

Chapter Eight: Plant Stem Cell Major Manufacturers Analysis

Chapter Nine: Development Trend of Analysis of Plant Stem Cell Market

Chapter Ten: Marketing Channel

Chapter Eleven: Conclusion

Continued here:
Plant Stem Cell Market- Growth Opportunities by Manufacturers, Regions, Type and Application; Trends Forecast to 2026 | Coherent Market Insights - The...

Global Regenerative Medicine Market Insights, Overview, Analysis and Forecast 2022 NeighborWebSJ – NeighborWebSJ

Regenerative Medicine Market Major Players:

Players active in the global regenerative medicine market include Osiris Therapeutics, Cook Biotech, Organogenesis, Baxter International, Inc., Stryker and RTI surgical, LifeSciences, CryoLife, Advanced Cell Technology, Sanofi, BioMimetic Therapeutics, Medtronic, StemCellsInc, and LifeCell Kinetic Concepts, among others.

ALSO READ :https://sapanas.tumblr.com/post/631130245458739200/regenerative-medicine-market-competitive-analysis

Regenerative Medicine Market Outlook

Global regenerative medicine market is growing continually, witnessing a massive uptake. Market growth primarily attributes to the increasing advancement in healthcare technology and the growing prevalence of chronic diseases. Besides, improvements in the field of regenerative medicine and stem cell technology drive the growth of the market excellently.

Moreover, the rising uptake of therapeutics such as stem cell biology, cellular therapy, tissue engineering in applications, including cord blood, oncology, urology, orthopedics, neurology, dermatology, and others accelerate the market growth. According to Market Research Future (MRFR), the global regenerative medicine market is poised to grow at 25.4% CAGR throughout the forecast period (2016 2022).

ALSO READ :https://yarabook.com/read-blog/138540

Additionally, the rising uptake of stem cell & tissue engineering processes in the treatment of health issues ranging from orthopedics, musculoskeletal & spine, dental, and skin/integumentary to cancer, neurology, and cardiology substantiate the market growth. Furthermore, the increasing rate of road accidents, injuries, and trauma cases drive the market exponentially, driving the demand for transplants & surgical reconstruction procedures.

On the other hand, factors such as the lack of awareness, skilled professionals, and stringent regulatory policies are projected to act as significant impeders for market growth. Nevertheless, funding support for the development of regenerative medicines would support the growth of the market throughout the predicted period. Also, widening application areas of regenerative medicines in the field of stem cell reconstructive and skin grafting would increase the market growth.

Global Regenerative Medicine Market Segments

The analysis is segmented into four dynamics;

By Material: Synthetic Materials, Genetically Engineered Materials, Pharmaceuticals, and others.

By Therapy: Stem Cell Biology, Cellular Therapy, Tissue Engineering, and others.

By Application: Cord Blood, Oncology, Urology, Orthopedics, Neurology, Dermatology, and others.

ALSO READ :http://www.marketwatch.com/press-release/fram-market-2021-industrytrends-opportunities-market-volume-competitive-landscape-possible-challenges-and-forecast-to-2025-2021-01-06

By Regions: Americas, Europe, Asia Pacific, Middle East & Africa, and Rest-of-the-World.

Regenerative Medicine Market Regional Analysis

North America is projected to continue dominating the globalregenerative medicine marketthroughout the forecast period. In 2015, North America accounted for more than 44% of the overall market share. This huge market growth attributes to the presence of a large number of major players and pharma & biotechnology companies. Moreover, huge investments made by public & private organizations drive the regenerative medicine industry in the region.

Besides, the rising prevalence of chronic diseases and orthopedic issues and increasing clinical trials to evaluate the therapeutic potential of products foster regional market growth. Also, the well-spread awareness towards the therapeutic potency of regenerative medicines impacts the market growth positively. The North American regenerative medicine market is expected to grow at a robust CAGR of 22.3% over the review period.

Europe stands second in the global regenerative medicine market. Factors such as the increasing per capita healthcare expenses and penetration of healthcare sectors in the region boost the market growth. Additionally, the rising government support and R&D funding in the life science developments substantiate the regional market growth. Markets in the UK, Germany, and France, contribute to the regional market majorly. The European regenerative medicine market is estimated to grow at 22.5% CAGR during the assessment period.

ALSO READ :http://www.marketwatch.com/press-release/m2m-communication-market-demand-to-rise-amid-industrial-automation-industry-analysis-with-business-trends-covid19-outbreak-competitor-strategyforecast-to-2023-2021-01-05

The Asia Pacific regenerative medicine market has emerged as a rapidly growing market. Factors such as the large advances in biotechnology and increasing government support for R&D are fostering the growth of the regional market. Regenerative medicine markets in highly populated countries such as China, India, and Japan support the regional market growth excellently, heading with huge technological advances. The APAC Regenerative Medicine market is predicted to demonstrate huge growth potential.

Global Regenerative Medicine Market Competitive Analysis

The well-established regenerative medicine market appears to be highly competitive with the presence of several notable players. To gain a larger competitive advantage, market players incorporate strategic initiatives such as mergers & acquisitions, expansions, and product/technology launch. Also, they make substantial investments to drive R&D to develop their capabilities and to expand their global footprints. Simultaneously, R&D funding programs initiated by the governments to enhance regenerative medicine capabilities are offering high growth potential. This is further going to attract several new entrants to the market and intensify the market competition further.

Regenerative Medicine Industry/Innovations/Related News:

March 15, 2020 - Research team at the University of Sheffield published their study on stem cell mutations that could improve regenerative medicine in the magazine Stem Cell Reports. Their study gives new insights into the cause of mutations in pluripotent stem cells and potential ways of stopping these mutations from occurring. It also suggests ways to reduce the likelihood of variations occurring in these cells when cultured. There is considerable interest in using Pluripotent stem cells to produce cells that can replace diseased or damaged tissues in applications referred to as regenerative medicine.

ALSO READ :http://www.marketwatch.com/press-release/waste-to-energy-market-share-size-key-players-regional-study-and-forecast-2024-2020-12-30

https://neighborwebsj.com/

Read the original post:
Global Regenerative Medicine Market Insights, Overview, Analysis and Forecast 2022 NeighborWebSJ - NeighborWebSJ

Seattle researchers find clues for treatments that could eliminate HIV in infected patients – GeekWire

Dr. Joshua Schiffer (third from left) and E. Fabian Cardozo-Ojeda (far right) led research published on Tuesday that provides mathematical models on strategies for optimizing treatment for HIV. (Fred Hutchinson Cancer Research Center Photo)

In the nearly four decades since HIV was discovered, only two people have been cured of the virus that has killed millions.

Researchers in Seattle are hoping to boost that number. On Tuesday, scientists from the Fred Hutchinson Cancer Research Center and the University of Washington published a study that provides clues to optimizing treatments that could wipe out HIV in infected patients.

Worldwide, some 26 million people are receiving antiviral therapy to keep the virus in check, but the drugs dont completely stamp out HIV, the virus that causes AIDS. The virus becomes latent, hiding out in cells until the drugs are gone. It gets activated again and starts reproducing.

One key component to HIVs reanimation is the presence of a molecule called CCR5 thats found on the outside of a certain class of immune system cells. The CCR5 helps the virus enter and infect new cells.

The two men seemingly cured of HIV, known as the Berlin Patient and the London Patient, also had cancer, one with acute myeloid leukemia and the other Hodgkin Lymphoma. As part of their cancer treatments, the patients received transplants of healthy stem cells, which produce immune system cells. They received the transplants from donors who lacked the gene that produces functional CCR5 molecules.

It appears that by suppressing the virus and then cutting off its pathway to resurgence, the virus can be defeated.

Since the 1960s, the Fred Hutch has been a pioneer in bone marrow transplants in cancer treatment, and researchers there are applying similar strategies for treating HIV.

Fred Hutch and UW scientists in recent years have performed experiments using pig-tailed macaques that are infected with a simian version of HIV. In one study of 22 monkeys, the infected macaques received transplants of their own stem cells, after they were treated to knock out the CCR5 gene. Researchers were interested in using the monkeys own altered cells because their immune systems would accept them and not perceive them as foreign invaders to be fought off.

One of the challenges of this approach to fighting HIV is figuring out how many of the altered stem cells are needed its difficult to produce a massive supply in order to overwhelm the cells that still produce CCR5. Add to that the rate of stem cell replication and figuring out the timing of administering and stopping antiviral drugs.

Thats where the new research comes in.

E. Fabian Cardozo-Ojeda, a senior staff scientist at the Fred Hutchs Vaccine and Infectious Disease Division, took all of the data available from the 22 monkeys to figure out how to perfect the treatment. He and his team developed a multi-stage mathematical model to calculate the effects of different amounts of residual and transplanted stem cells, the HIV viral load and the timing of when antiviral drugs are halted.

Were trying to do interdisciplinary work to get that optimal approach for a cure, Cardozo-Ojeda said.

In order to control HIV through this strategy, the researchers came to two conclusions with their formula. First, a patient needs a dose of at least five times as many transplanted stem cells compared to residual cells, and second, before a patient stops taking antiviral drugs, the cells lacking CCR5 need to total between 76-to-94% of the total transplanted stem cell population in their blood.

While the study was based on macaque data, were generating possible hypotheses of what could happen with people, Cardozo-Ojeda said. When it comes to applying their formula to higher primates, we believe that could be translated to humans for sure.

The peer-reviewed study was published by eLife, a non-profit platform. Cardozo-Ojeda is first author of the study and the other authors are Elizabeth Duke, Christopher Peterson, Daniel Reeves, Bryan Mayer, Hans-Peter Kiem and Joshua Schiffer.

More:
Seattle researchers find clues for treatments that could eliminate HIV in infected patients - GeekWire

Can Retinol and Niacinamide Be Used Together? Here’s What the Experts Had to Say – POPSUGAR

Whether you follow a strict 10-step routine or prefer the upmost minimalism, finding your failsafe skin care can be a complex process of trial and error. With so many products on the market, not only do you need to find those that work best for your skin type, but you also need to ensure the ingredients play well together, too. Similarly to retinol, the benefits of niacinamide seem to hold no bounds, but the big question is: can these two powerhouse ingredients be used together?

In case you needed a reminder, Daniel Isaacs, director of research at Medik8, told us that retinol is the classic form of vitamin A and the unequivocal gold standard for tackling multiple skin concerns.

"Retinol stimulates cellular turnover in the skin, pushing fresh skin cells to the surface and [enhancing] collagen production." The powerful combination means that when used in topical skin care, retinol can reduce acne, smooth uneven skin texture, and brighten stubborn scarring. "Retinol is second to none for improving signs of photo-aging as it helps block the formation of pigment in the skin for brighter, more even-toned skin."

Despite all the virtues of retinol, it is also well known for being irritating if you're new to the ingredient, have overused it, or are using a formula with a high concentration, according to dermatologist Dr. Cristina Psomadakis. "Common side effects of retinol include redness, flaking and increased skin sensitivity," she told POPSUGAR.

Thankfully, using niacinamide in your skin-care routine can help combat the negative side effects of retinol. Also known as vitamin B3, consultant dermatologist Dr. Justine Hextall explained that niacinamide is another multipurpose powerhouse ingredient.

"Niacinamide is a great anti-inflammatory and can help to improve uneven skin tone, diminish dullness, and soften fine lines and wrinkles. It's also crucial for healthy functioning of the skin barrier as it boosts ceramide production and reduces trans-epidermal water loss, which are key elements of reinforcing our skin barrier, keeping our skin hydrated, and improving redness and sensitivity from retinol usage."

Not only can niacinamide be used alongside retinol treatment to make it more tolerable, but Dr. Psomadakis also explained that niacinamide can also act as a preretinol skin trainer. "Research shows that pretreating your skin with niacinamide for a few weeks before starting retinol reduces the likelihood of side effects because your skin barrier will be in better shape."

Although the dynamic duo of niacinamide and retinol pair very well together, Dr. Hextall advised people to still be cautious. "I always recommend a low and slow approach with retinol, and this shouldn't change just because you are using a compensating ingredient. It's always best to respect the skin barrier and build up your actives." Dr. Psomadakis agreed, pointing out that there are very few skin-care absolutes that apply to everyone. "Overall, niacinamide is very well tolerated and is known to be calming but there will always be exceptions." She also added that although niacinamide can help you tolerate retinol, it doesn't work the other way around. "If niacinamide on its own doesn't suit you, combining it with retinol won't change things."

When it comes to pairing the two together, you can either use two separate products or one product that contains both retinol or niacinamide. Those with more sensitive skins or are new to retinoids may prefer a handy duo according to Dr Hextall. "It is often thought that retinol is only for robust skins, however, using a clever formulation that combines cushioning niacinamide, can help to mitigate sensitivity." With niacinamide available in variety of products from face washes, to serums, hydrating toners and moisturizers, how you pair the two together is a matter of preference, but Isaacs said the typical skin-care layering rules still apply.

"The golden rule is to begin with the lightest formulation and build up layers with heavier textures so the heavier products can penetrate through the lighter ones to be properly absorbed. Start with water based products, follow with oil, emulsions, and finish with heavier creams." As always, but especially when using retinols, make sure to use a broad spectrum SPF in the daytime, too.

Ahead, find our favorite retinol and niacinamide products to take your skincare routine up a notch.

Here is the original post:
Can Retinol and Niacinamide Be Used Together? Here's What the Experts Had to Say - POPSUGAR

Archives